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SCIENTIFIC OPINION 
Scientific opinion on Flavouring Group Evaluation 24, Revision 2 
(FGE.24Rev2): 
Pyridine, pyrrole, indole and quinoline derivatives from chemical group 28
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate 24 flavouring substances in the Flavouring Group Evaluation 24, Revision 
2, using the Procedure in Commission Regulation (EC) No 1565/2000. This revision was made required owing 
to the inclusion of the assessment of new toxicity data on one supporting substance, 2-acetylpyrrole [FL-no: 
14.047], to support the re-evaluation of one candidate substance, 2-acetyl-5-methylpyrrole [FL-no: 14.085]. Nine 
of the original 33 candidate substances [FL-no: 13.100, 14.002, 14.023, 14.094, 14.107, 14.138, 14.145, 14.163 
and 14.169], for which additional data were requested, are no longer supported by Industry for use as flavouring 
substances in Europe and will therefore not be considered any further. None of the 24 substances were 
considered to have genotoxic potential. These candidate substances were evaluated through a stepwise approach 
that integrates information on the structure-activity relationships, intake from current uses, toxicological 
threshold of concern, and available data on metabolism and toxicity. The Panel concluded that the 24 substances 
[FL-no: 14.085, 14.088, 14.089, 14.092, 14.093, 14.103, 14.104, 14.105, 14.106, 14.110, 14.115, 14.116, 
14.117, 14.118, 14.120, 14.124, 14.125, 14.131, 14.134, 14.135, 14.136, 14.140, 14.143 and 14.150] do not give 
rise to safety concern at their levels of dietary intake, estimated on the basis of the MSDI approach. Besides the 
safety assessment of these flavouring substances, the specifications for the materials of commerce have also been 
considered. Adequate specifications including complete purity criteria and identity for the materials of 
commerce have been provided for all 24 candidate substances. 
© European Food Safety Authority, 2013 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to deliver a scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 24 flavouring substances in the 
Flavouring Group Evaluation 24, Revision 2 (FGE.24Rev2), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. These 24 derivatives of pyridine, pyrrole, indole and 
quinoline belong to chemical group 28, Annex I of the Commission Regulation (EC) No 1565/2000.  
The present revision of FGE.24, FGE.24Rev2, includes the assessment of new toxicity data on one 
supporting substance, 2-acetylpyrrole [FL-no: 14.047], to cover the re-evaluation of one candidate 
substance, 2-acetyl-5-methylpyrrole [FL-no: 14.085], for which additional data were required.  
Since the publication of the previous version of FGE.24, FGE.24Rev1, nine of the original 33 
candidate substances [FL-no: 13.100, 14.002, 14.023, 14.094, 14.107, 14.138, 14.145, 14.163 and 
14.169], for which additional data were required, are no longer supported by Industry for use as 
flavouring substances in Europe and will therefore not be considered any further. This revision of 
FGE.24, FGE.24Rev2, therefore deals only with 24 candidate substances. 
None of the 24 candidate substances can exist as geometrical or optical isomers. 
Twenty-two of the candidate substances are classified into structural class II and two are classified 
into structural class III. 
Twenty-one candidate substances in the present group have been reported to occur naturally in a wide 
range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided to also perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels.  
According to the default MSDI approach, the 24 candidate substances in this group have intakes in 
Europe from 0.0012 to 0.73 µg/capita/day, which are all below the thresholds of concern for both 
structural class II (540 µg/person/day) and structural class III (90 µg/person/day) substances. 
The genotoxicity data available for the candidate substances do not preclude their evaluation through 
the Procedure. 
Two of the 24 candidate substances evaluated through the Procedure, ethyl nicotinate [FL-no: 14.110] 
and isopropyl nicotinate [FL-no: 14.120], are expected to be metabolised to innocuous products. For 
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the remaining 22 candidate substances it cannot be anticipated that they will be metabolised to 
innocuous products.  
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure.  
It was considered that, on the basis of the default MSDI approach, the 24 substances, to which the 
Procedure was applied would not give rise to safety concerns at the estimated levels of intake arising 
from their use as flavouring substances. 
When the estimated intakes were based on the mTAMDI approach they are 400 µg/person/day for 
each of the 22 candidate substances from structural class II, which is below the threshold of concern 
for structural class II of 540 µg/person/day. For the two flavouring substances [FL-no: 14.088 and 
14.131] assigned to structural class III, the estimated intakes based on the mTAMDI are 400 
µg/person/day each. This is above the threshold of concern for structural class III of 90 µg/person/day. 
For the two candidate substances 1-acetylindole [FL-no: 14.088] and 2-methylindole [FL-no: 14.131], 
the intakes, estimated on the basis of the mTAMDI, exceed the threshold for the structural class to 
which the flavouring substance has been assigned. Therefore, for these two substances more reliable 
exposure data are required. On the basis of such additional data, these flavouring substances should be 
reconsidered along the steps of the Procedure. Following this procedure, additional toxicological data 
might become necessary. 
In order to determine whether the conclusion for the 24 candidate substances could be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity tests for the materials of commerce have been provided 
for all 24 candidate substances.  
Based on the available data, the Panel concluded that the 24 candidate substances [FL-no: 14.085, 
14.088, 14.089, 14.092, 14.093, 14.103, 14.104, 14.105, 14.106, 14.110, 14.115, 14.116, 14.117, 
14.118, 14.120, 14.124, 14.125, 14.131, 14.134, 14.135, 14.136, 14.140, 14.143 and 14.150]  
evaluated through the Procedure would present no safety concern at the estimated levels of intake 
based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA has evaluated 33 flavouring substances in the flavouring group evaluation 24 (FGE.24) and its 
revision. The last opinion was adopted on 27 September 2007. EFSA concluded in its opinion that for 
2-acetyl-5-methylpyrrole [FL-no: 14.085] additional toxicological data are required. 
EFSA has considered the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) 
evaluation of 26 pyridine, pyrrole and quinoline derivatives evaluated in the flavouring group 
evaluation 77 (FGE.77). The opinion was adopted on 31 January 2008. EFSA concluded in its opinion 
that for 2-acetylpyrrole [FL-no: 14.047] and 2-propionylpyrrole [FL-no: 14.068], No Observed 
Adverse Effect Levels (NOAELs) could not be derived as such or for structurally related substances. 
Accordingly, additional toxicological data are required for these substances. 
The requested information on the representative material, 2-acetylpyrrole [FL-no: 14.047], has now 
been submitted by the European Flavour Association. This information is intended to cover the re-
evaluation of this substance and of 2-propionylpyrrole [FL-no: 14.068] from FGE.77. In addition, it 
should cover the re-evaluation of 2-acetyl-5-methylpyrrole [FL-no: 14.085] from FGE.24. 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests European Food Safety Authority (EFSA) to carry out a safety 
assessment on the following three flavouring substances:  2-acetylpyrrole [FL-no: 14.047], 2-
propionylpyrrole [FL-no: 14.068] and 2-acetyl-5-methylpyrrole [FL-no: 14.085] in accordance with 
Commission Regulation (EC) No 1565/2000. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Official Journal of the European 
Communities 31.12.2008, L 354/34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. Official Journal of the 
European Communities 2.10.2012, L 267, 1-161.OJ L 267, 2.10.2012, p. 1. 
6 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities 
19.7.2000, L 180, 8-16. 
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ASSESSMENT 
1. History of the Evaluation of the Substances in the Present FGE  
The first version of the Flavouring Group Evaluation 24 (FGE.24) dealt with 31 derivatives of 
pyridine, pyrrole, indole and quinoline. 
The first revision of FGE.24 (FGE.24Rev1) included the assessment of two additional candidate 
substances [FL-no: 14.163 and 14.169]. No studies on toxicology or on metabolism for these two 
candidate substances were identified. 
The data available gave rise to some concern regarding the genotoxic potential of the quinoline 
derivatives [FL-no: 14.002, 14.094 and 14.138], and accordingly the Panel concluded that the 
Procedure could not be applied to these three substances until adequate in vivo data become available. 
For seven candidate substances [FL-no: 13.100, 14.023, 14.085, 14.107, 14.145, 14.163 and 14.169], a 
No Observed Adverse Effect Level (NOAEL) could not be derived for the substance or a structurally 
related substance. Accordingly, additional data were required for these seven flavouring substances.  
Since the publication of FGE.24Rev1, nine [FL-no: 13.100, 14.002, 14.023, 14.094, 14.107, 14.138, 
14.145, 14.163 and 14.169] of the 33 candidate substances are no longer supported for use as 
flavouring substances in Europe by Industry (EFSA, 2011; DG SANCO, 2013) and will therefore not 
be considered any further. The nine substances are listed here below. Accordingly, FGE.24Rev2 only 
deals with 24 candidate substances. 
The nine substances deleted: 
FL-no EU Register name 
13.100 2-Acetyl-1-furfurylpyrrole 
14.002 4-Methylquinoline 
14.023 1-Methylpyrrole 
14.094 4-Butylquinoline 
14.107 2,5-Dimethylpyrrole 
14.138 2-Methylquinoline 
14.145 Pyrrole-2-carbaldehyde 
14.163 1-Methylpyrrole-2-carboxaldehyde 
14.169 1-Ethyl-2-pyrrolecarboxaldehyde 
These nine substances will be excluded in the following text except in tables 1 and 7. Information in 
the text on these substances will only be kept if relevant for the remaining candidate substances. 
As a consequence of this, the following supporting substances have been deleted from this revision: 
FL-no 
JECFA no 
EU Register name 
 
Structural formula 
- 
- 
8-Methylquinoline 
N
 
13.134 
1310 
1-Furfurylpyrrole N
O
 
14.042 
1302 
6-Methylquinoline 
N
 
The table below gives information on publication date and links to the published versions.   
FGE Opinion 
adopted 
by EFSA 
Link No. of 
candidate 
substances 
FGE.24 4 May 2006 http://www.efsa.europa.eu/EFSA/Scientific_Opinion/afc_op_ej372_fge 31 
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24_op_en,0.pdf 
FGE.24Rev1 26 Sept. 
2007 
http://www.efsa.europa.eu/EFSA/ScientificPanels/AFC/efsa_locale-
1178620753812_Opinions425.htm 
33 
FGE.24Rev2 25 October 
2013 
 24 
The present Revision of FGE.24, FGE.24Rev2, considers the re-evaluation of one candidate 
substance, 2-acetyl-5-methylpyrrole [FL-no: 14.085]. Additional information was provided to the 
Panel of a 90-day study on one supporting substance, 2-acetylpyrrole [FL-no: 14.047] which is 
structurally related to the candidate substance 2-acetyl-5-methylpyrrole [FL-no: 14.085]. A search in 
open literature was conducted for metabolism, genotoxicity and toxicity for 2-acetyl-5-methylpyrrole 
[FL-no: 14.085]. This search did not reveal any pertinent new information on the substance. 
2. Presentation of the Substances in Flavouring Group Evaluation 24, Revision 2 
2.1. Description 
The present Flavouring Group Evaluation 24, Revision 2 (FGE24Rev2) using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000) (The Procedure – shown in 
schematic form in Appendix A), deals with 24 derivatives of pyridine, pyrrole and indole from 
chemical group 28, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000).  
The 24 flavouring substances have one heterocyclic N-atom in a five or six-membered ring structure. 
Twenty-two of the compounds are monocyclic, with either a five-membered ring (pyrroles) [FL-no: 
14.085] or a six-membered ring (pyridines) [FL-no: 14.089, 14.092, 14.093, 14.103, 14.104, 14.105, 
14.106, 14.110, 14.115, 14.116, 14.117, 14.118, 14.120, 14.124, 14.125, 14.134, 14.135, 14.136, 
14.140, 14.143 and 14.150]. The remaining two candidate substances are aromatic bicyclic structures 
consisting of one six- or one five-membered ring (indoles) [FL-no: 14.088 and 14.131]. The 
substances are substituted with simple alkyl, alcohol, ketone or ester moieties. 
The 24 flavouring substances under consideration, as well as their chemical Register names, FLAVIS- 
(FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract 
Manufactures Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
A summary of the outcome of the safety evaluation of the candidate substances are listed in Table 7. 
The hydrolysis products of the two esters [FL-no: 14.110 and 14.120] and the amide [FL-no: 14.088] 
contained in the present FGE as well as their evaluation status are listed in Table 8. 
The 24 flavouring substances (candidate substances) are structurally closely related to 15 flavouring 
substances (supporting substances) evaluated at the 63rd JECFA meeting (JECFA, 2006) in the group 
of “Pyridine, pyrrole and quinoline derivatives”. One other structurally related flavouring substance 
(indole-3-carbinol) is also included as supporting substance in this evaluation. The supporting 
substances are listed in Table 9. 
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 24, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
13.100 
 
2-Acetyl-1-furfurylpyrrole 
N
O
O
 
 
11941 
13678-73-4 
Solid 
C11H11NO2 
189.21 
Practically 
insoluble or 
insoluble 
Freely soluble 
101 (0.04 hPa) 
42 
NMR 
95 % 
n.a. 
n.a. 
 
No longer supported 
by Industry  
(EFSA, 2011). 
14.002 
 
4-Methylquinoline 
N
 
 
488 
491-35-0 
Liquid 
C10H9N 
143.19 
Slightly soluble 
Freely soluble 
264 
9 
MS 
95 % 
1.615-1.621 
1.083-1.089 
 
No longer supported 
by Industry  
(EFSA, 2011). 
14.023 
 
1-Methylpyrrole 
N
 
 
2217 
96-54-8 
Liquid 
C5H7N 
81.12 
Practically 
insoluble or 
insoluble 
Freely soluble 
113 
 
MS 
99 % 
1.482-1.490 
0.902-0.914 
 
No longer supported 
by Industry  
(EFSA, 2011). 
14.085 
 
2-Acetyl-5-methylpyrrole 
H
N
O
 
 
 
6982-72-5 
Solid 
C7H9NO 
123.15 
Practically 
insoluble or 
insoluble 
Freely soluble 
240 
88 
MS 
95 % 
n.a. 
n.a. 
 
 
14.088 
 
1-Acetylindole 
N
O
 
 
 
576-15-8 
Liquid 
C10H9NO 
159.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
144 (13 hPa) 
 
MS 
95 % 
1.607-1.613 
1.384-1.390 
 
 
14.089 
 
4-Acetylpyridine 
N
O  
 
 
1122-54-9 
Liquid 
C7H7NO 
121.14 
Practically 
insoluble or 
insoluble 
Freely soluble 
212 
 
MS 
95 % 
1.520-1.526 
1.098-1.104 
 
 
14.092 
 
2-Butylpyridine 
N
 
 
 
5058-19-5 
Liquid 
C9H13N 
135.21 
Practically 
insoluble or 
insoluble 
Freely soluble 
190 
 
MS 
95 % 
1.487-1.493 
0.911-0.917 
 
 
14.093 
 
3-Butylpyridine 
N
 
 
 
539-32-2 
Liquid 
C9H13N 
135.21 
Practically 
insoluble or 
insoluble 
Freely soluble 
206 
 
MS 
95 % 
1.492-1.498 
0.909-0.915 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 24, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
14.094 
 
4-Butylquinoline 
N
 
 
 
74808-78-9 
Solid 
C13H15N 
185.27 
Practically 
insoluble or 
insoluble 
Freely soluble 
328 
30 
NMR 
95 % 
n.a. 
n.a. 
 
No longer supported 
by Industry  
(EFSA, 2011). 
14.103 
 
2,3-Dimethylpyridine 
N
 
 
 
583-61-9 
Liquid 
C7H9N 
107.15 
Slightly soluble 
Freely soluble 
161 
 
MS 
95 % 
1.503-1.509 
0.943-0.949 
 
 
14.104 
2151 
2,4-Dimethylpyridine 
N
 
4389 
 
108-47-4 
Liquid 
C7H9N 
107.15 
Slightly soluble 
Freely soluble 
156 
 
MS 
95 % 
1.496-1.502 
0.929-0.935 
 
 
14.105 
 
3,4-Dimethylpyridine 
N
 
 
 
583-58-4 
Liquid 
C7H9N 
107.15 
Slightly soluble 
Freely soluble 
176 
 
MS 
95 % 
1.507-1.513 
0.954-0.960 
 
 
14.106 
 
3,5-Dimethylpyridine 
N
 
 
11382 
591-22-0 
Liquid 
C7H9N 
107.15 
Slightly soluble 
Freely soluble 
170 
 
MS 
95 % 
1.500-1.506 
0.939-0.945 
 
 
14.107 
 
2,5-Dimethylpyrrole 
H
N
 
 
11383 
625-84-3 
Liquid 
C6H9N 
95.14 
Practically 
insoluble or 
insoluble 
Freely soluble 
168 
 
MS 
95 % 
1.500-1.506 
0.929-0.935 
 
No longer supported 
by Industry  
(EFSA, 2011). 
14.110 
 
Ethyl nicotinate 
N
O
O
 
 
 
614-18-6 
Liquid 
C8H9NO2 
151.16 
Slightly soluble 
Freely soluble 
224 
9 
MS 
95 % 
1.498-1.504 
1.105-1.111 
 
 
14.115 
 
2-Ethylpyridine 
N
 
 
11767 
100-71-0 
Liquid 
C7H9N 
107.15 
Practically 
insoluble or 
insoluble 
Freely soluble 
149 
 
MS 
95 % 
1.494-1.500 
0.927-0.937 
 
 
14.116 
 
4-Ethylpyridine 
N
 
 
11387 
536-75-4 
Liquid 
C7H9N 
107.15 
Practically 
insoluble or 
insoluble 
Freely soluble 
166 
 
MS 
95 % 
1.496-1.502 
0.939-0.945 
 
 
14.117 
 
2-Hexylpyridine 
N
 
 
 
1129-69-7 
Liquid 
C11H17N 
163.26 
Practically 
insoluble or 
insoluble 
111 (20 hPa) 
 
MS 
1.480-1.490 
0.892-0.902 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 24, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
Freely soluble 95 % 
14.118 
 
2-Hydroxypyridine 
N OH
 
 
 
142-08-5 
Solid 
C5H5NO 
95.10 
Slightly soluble 
Freely soluble 
281 
107 
MS 
95 % 
n.a. 
n.a. 
 
 
14.120 
 
Isopropyl nicotinate 
N
O
O
 
 
 
553-60-6 
Liquid 
C9H11NO2 
165.19 
Slightly soluble 
Freely soluble 
110 (9 hPa) 
 
MS 
95 % 
1.498-1.504 
1.061-1.067 
 
 
14.124 
 
2-Isopropylpyridine 
N
 
 
11400 
644-98-4 
Liquid 
C8H11N 
121.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
156 
 
MS 
95 % 
1.488-1.494 
0.931-0.937 
 
 
14.125 
 
4-Isopropylpyridine 
N
 
 
 
696-30-0 
Liquid 
C8H11N 
121.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
180 
 
MS 
95 % 
1.492-1.498 
0.923-0.929 
 
 
14.131 
 
2-Methylindole 
H
N
 
 
 
95-20-5 
Solid 
C9H9N 
131.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
273 
60 
MS 
95 % 
n.a. 
n.a. 
 
 
14.134 
 
2-Methylpyridine 
N
 
 
11415 
109-06-8 
Liquid 
C6H7N 
93.13 
Practically 
insoluble or 
insoluble 
Freely soluble 
128 
 
MS 
95 % 
1.494-1.500 
0.941-0.947 
 
 
14.135 
 
3-Methylpyridine 
N
 
 
11801 
108-99-6 
Liquid 
C6H7N 
93.13 
Practically 
insoluble or 
insoluble 
Freely soluble 
143 
 
MS 
95 % 
1.496-1.502 
0.953-0.959 
 
 
14.136 
 
4-Methylpyridine 
N
 
 
11416 
108-89-4 
Liquid 
C6H7N 
93.13 
Practically 
insoluble or 
insoluble 
Freely soluble 
142 
 
MS 
95 % 
1.500-1.506 
0.951-0.957 
 
 
14.138 
 
2-Methylquinoline 
N
 
 
11358 
91-63-4 
Liquid 
C10H9N 
143.19 
Slightly soluble 
Freely soluble 
246 
 
MS 
95 % 
1.608-1.614 
1.055-1.061 
 
No longer supported 
by Industry  
(EFSA, 2011). 
14.140 
 
3-Pentylpyridine 
N
 
 
 
Liquid 
C10H15N 
Practically 
insoluble or 
100 (12 hPa) 
 
1.486-1.492 
0.905-0.911 
 
 
Flavouring Group Evaluation 24, Revision 2 
 
EFSA Journal 2013;11(11):3453 11 
Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 24, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
1802-20-6 149.24 insoluble 
Freely soluble 
MS 
95 % 
14.143 
 
3-Propylpyridine 
N
 
 
11419 
4673-31-8 
Liquid 
C8H11N 
121.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
181 
 
MS 
95 % 
1.493-1.499 
0.922-0.928 
 
 
14.145 
 
Pyrrole-2-carbaldehyde 
H
N
O
 
 
11393 
1003-29-8 
Solid 
C5H5NO 
95.10 
Sparingly soluble 
Freely soluble 
218 
46 
MS 
95 % 
n.a. 
n.a. 
 
No longer supported 
by Industry  
(DG SANCO, 2013). 
14.150 
 
2,4,6-Trimethylpyridine 
N
 
 
 
108-75-8 
Liquid 
C8H11N 
121.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
168 
 
MS 
95 % 
1.493-1.499 
0.910-0.916 
 
 
14.163 
2152 
1-Methylpyrrole-2-
carboxaldehyde 
N
O
 
4332 
 
1192-58-1 
Liquid 
C6H7NO 
109.13 
Very slightly 
soluble 
Freely soluble 
192-194 
 
IR NMR MS 
98 % 
1.558-1.564 
1.012-1.018 
 
No longer supported 
by Industry  
(DG SANCO, 2013). 
14.169 
2150 
1-Ethyl-2-
pyrrolecarboxaldehyde N
O
 
4317 
 
2167-14-8 
Liquid 
C7H9NO 
123.15 
Slightly soluble 
Freely soluble 
205 
 
NMR 
99 % 
1.541-1.547 
1.033-1.039 
 
No longer supported 
by Industry  
(DG SANCO, 2013). 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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2.2. Stereoisomers 
None of the 24 candidate substances can exist as geometrical or optical isomers. 
2.3. Natural Occurrence in Food 
Twenty-one out of 24 flavouring substances have been reported to occur in one or more of the 
following food items: tea, coffee, cocoa, fruits, almond, nuts, bread, asparagus, cheese, milk powder, 
pork, chicken, beef, shrimps, beer, whisky, wine, rum, malt, popcorn and peppermint oil. Quantitative 
data on the natural occurrence in food have been reported for 12 of the 21 candidate substances (Table 
2) 
Table 2:  Candidate Substances Reported to Occur in Food (TNO, 2000) 
FL-no: Name: Quantitative data reported 
14.085 2-Acetyl-5-methylpyrrole 0.3 mg/kg in coffee, 0.02 mg/kg in malt 
14.103 2,3-Dimethylpyridine 0.00008 mg/kg in pork, 2 mg/kg in tea 
14.104 2,4-Dimethylpyridine Trace amounts in chicken, up to 0.00005 mg/kg in pork, 0.002 mg/kg 
in shrimps 
14.105 3,4-Dimethylpyridine Up to 0.0002 mg/kg in whisky 
14.106 3,5-Dimethylpyridine Up to 0.15 mg/kg in tea 
14.110 Ethyl nicotinate Up to 0.06 mg/kg in apricot, up to 0.05 mg/kg in arctic bramble, up 
to 1.4 mg/kg in beer, up to 0.3 mg/kg in papaya 
14.115 2-Ethylpyridine Trace amounts in asparagus, 0.0001 mg/kg in pork 
14.116 4-Ethylpyridine 0.0005 mg/kg in pork 
14.134 2-Methylpyridine 0.08 mg/kg in cheese, 0.0005 mg/kg in chicken, 0.0003 mg/kg in 
pork, up to 0.02 mg/kg in shrimps, 0.002 mg/kg in whisky 
14.135 3-Methylpyridine 0.0008 mg/kg in beer, 1.3 mg/kg in coffee and up to 0.0006 mg/kg in 
whisky 
14.136 4-Methylpyridine 0.0001 mg/kg in pork, trace amounts in shrimps 
14.150 2,4,6-Trimethylpyridine Up to 0.15 mg/kg in tea 
 
Three of the 24 substances have not been reported to occur naturally in any food items according to 
TNO (TNO, 2000) (Table 3).  
Table 3:  Candidate Substances Not Reported to Occur in Food (TNO, 2000) 
FL-no: Name: 
14.088 1-Acetylindole 
14.120 Isopropyl nicotinate 
14.125 4-Isopropylpyridine 
3. Specifications 
Purity criteria for the 24 candidate substances have been provided by the Flavouring Industry (EFFA, 
2004b) (Table 1). 
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Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), the information is adequate for all of the candidate substances (see Section 2.2 and Table 1). 
4. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in 
the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability 
of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004). 
4.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry (IOFI), in which flavour 
manufacturers reported the total amount of each flavouring substance incorporated into food sold in 
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible 
natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population7 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
                                                     
7   EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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In the present Flavouring Group Evaluation 24, Revision 2 (FGE.24Rev2), the total annual production 
volume of the 24 candidate substances from use as flavouring substances in Europe was reported to be 
12 kg (EFFA, 2004c; Flavour Industry, 2005). For the 15 supporting substances the total annual 
volume of production in Europe is approximately 980 kg (JECFA, 2006).  
On the basis of the annual volumes of production reported for the 24 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated (Table 6 and 7). More than 50 % 
(7.7 kg) of the total annual volume of production for the candidate substances (EFFA, 2004c) is 
accounted for by 4-methylpyridine [FL-no: 14.136] and 2-methylpyridine [FL-no: 14.134]. The 
estimated daily per capita intakes of these candidate substances from use as flavouring substances are 
0.73 and 0.21 µg, respectively. The daily per capita intakes for each of the remaining substances are 
less than 0.15 µg (Table 6 and Table 7). 
4.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of the modified mTAMDI values is based on the approach used by SCF up 
to 1995 (SCF, 1995).  
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the 24 candidate substances, information on food categories and normal 
and maximum use levels
8,9,10
 were submitted by the Flavour Industry (EFFA, 2004b; EFFA, 2007; 
Flavour Industry, 2005). The 24 candidate substances are used in flavoured food products divided into 
the food categories outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 
2000), as shown in Table 4. For the present calculation of mTAMDI, the reported normal use levels 
were used. In cases where different use levels were reported for different food categories the highest 
reported normal use level was used. 
Table 4:  Use of Candidate Substances in Various Food Categories for 24 Candidate 
Substances for which Data on Use have been provided 
                                                     
8  Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile  
 ``of reported usages (EFFA, 2002). 
9  The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from  
 ``figures derived from 12 model flavouring substances (EFFA, 2004a). 
10 The use levels from food category 5 “Confectionery” have been inserted as default values for food category  
 ``14.2 “Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA,  
 ``2007). 
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Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All 24 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All 24  
03.0 Edible ices, including sherbet and sorbet All 24 
04.1 Processed fruits All 24  
04.2 Processed vegetables (including mushrooms and fungi, roots and tubers, pulses 
and legumes), and nuts and seeds 
None 
05.0 Confectionery All 24 
06.0 Cereals and cereal products, including flours and starches from roots and 
tubers, pulses and legumes, excluding bakery 
All 24 
07.0 Bakery wares All 24 
08.0 Meat and meat products, including poultry and game All 24  
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All 24 except [FL-no: 
14.115] 
10.0 Eggs and egg products Only [FL-no: 14.115] 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All 24 
13.0 Foodstuffs intended for particular nutritional uses All 24 
14.1 Non-alcoholic ("soft") beverages, excluding dairy products All 24 
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts All 24 
15.0 Ready-to-eat savouries All 24 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
All 24 
 
According to the Flavour Industry the normal use levels for the 24 candidate substances are in the 
range of 0.1 - 2 mg/kg food, and the maximum use levels are in the range of 0.5 - 10 mg/kg (EFFA, 
2004b; EFFA, 2007; Flavour Industry, 2005).  
The mTAMDI value is 400 µg/person/day for each of the 22 candidate substances from structural 
class II and for the two candidate substances from structural class III. For detailed information on use 
levels and intake estimations based on the mTAMDI approach, see Section 7 and Appendix B. 
5. Absorption, Distribution, Metabolism and Elimination 
The 24 candidate substances are divided into four subgroups with more closely related structural 
properties within the subgroups as shown in Table 5 (The substances previously allocated to subgroup 
2 and 6 are no longer supported by Industry (See Section 1)). 
Table 5:  Candidate Substances Divided into Groups of Related Chemical Structures 
Subgroup Candidate substance FL-no Chemical 
group 
1 2-Acetyl-5-methylpyrrole 14.085 Pyrroles 
2 
The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry 
 
 
 
N-substituted 
pyrroles  
3 
2-Methylindole 14.131 
Indoles 1-Acetylindole 14.088 
4 
2-Methylpyridine 14.134 
Pyridines with 
alkyl, hydroxyl 
or acetyl  
groups 
3-Methylpyridine 14.135 
4-Methylpyridine 14.136 
2-Ethylpyridine 14.115 
4-Ethylpyridine 14.116 
3-Propylpyridine 14.143 
2-Isopropylpyridine 14.124 
4-Isopropylpyridine 14.125 
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2-Butylpyridine 14.092 
3-Butylpyridine 14.093 
3-Pentylpyridine 14.140 
2-Hexylpyridine 14.117 
2,3-Dimethylpyridine 14.103 
2,4-Dimethylpyridine 14.104 
3,4-Dimethylpyridine 14.105 
3,5-Dimethylpyridine 14.106 
2,4,6-Trimethylpyridine 14.150 
2-Hydroxypyridine 14.118 
4-Acetylpyridine 14.089 
5 
Ethyl nicotinate 14.110 Pyridines with 
ester groups Isopropyl nicotinate 14.120 
6 
The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry  
 
 Quinolines 
 
Subgroup 1: The group contains one pyrrol derivative, 2-acetyl-5-methylpyrrole [FL-no: 14.085]. 
Further oxidation of the acetyl group is expected. According to (Damani and Crooks, 1982) pyrroles 
are likely substrates for enzymatic oxidation at N1. 
Subgroup 3: The group contains two indole derivatives, 1-acetylindole [FL-no: 14.088] (an amide) and 
2-methylindole [FL-no: 14.131]. No data are available on the hydrolysis of 1-acetylindole [FL-no: 
14.088] or structurally related substances. Amides are known to be hydrolysed but less rapidly than 
esters. A rapid hydrolysis of 1-acetylindole in the gastro-intestinal tract is not anticipated although 
hydrolysis by amidases in the tissues might be expected. The candidate substance 2-methylindole [FL-
no: 14.131] and indole, the hydrolysis product of 1-acetylindole [FL-no: 14.088], will be metabolised 
through two main pathways. Oxidation of the methyl group in 2-methylindole and in the ring structure 
is anticipated, resulting in introduction of hydroxyl groups which are conjugated with glucuronic acid 
or sulphate. Epoxidation of the double bonds on the pyrrole ring is also expected, leading to oxindole 
compounds which can be further hydroxylated and conjugated with glucuronic acid or sulphate. The 
supporting substance 3-methylindole is anticipated to be metabolised to the reactive metabolite 3-
methyleneindolenine which is conjugated with glutathione. Since a methyleneindolenine is not 
expected to be formed from 2-methylindole, conjugation with glutathione is unlikely for this 
substance.  
Subgroup 4: The group contains 19 pyridine derivatives substituted with alkyl, hydroxyl or acetyl 
groups. Two main metabolism pathways can be predicted for the alkyl substituted pyridines. The main 
pathway is hydroxylation of the alkyl groups, with additional oxidation to the corresponding carboxyl 
compounds. The carboxyl metabolites are excreted in the urine as such or conjugated with glycine. 
Alternatively the candidate pyridines may be oxidised on the nitrogen atom, and excreted in the urine 
without conjugation. Hydroxylation of the pyridine ring through epoxide intermediates cannot be 
excluded, although it has not been shown to be a major pathway of the supporting substances 3-
ethylpyridine, 2,3-dimethylpyridine and 2,6-dimethylpyridine However, this is probably dependent on 
the positions of the substitutions. From the metabolism studies on the supporting substance 3-
acetylpyridine, the major metbolic pathway for 4-acetylpyridine [FL-no: 14.089] is expected to be via 
reduction of the keto group followed by conjugation by glucoronic acid and excretion via the urine. To 
a minor extend, N-oxidation or N-methylation may take place. 2-Hydroxypyridine [FL-no: 14.118] is 
expected to be excreted as such or as conjugate. 
Subgroup 5: The group contains two esters of nicotinic acid, ethyl nicotinate [FL-no: 14.110] and 
isopropyl nicotinate [FL-no: 14.120], which are expected to be hydrolysed in vivo to nicotinic acid and 
ethanol, and to nicotinic acid and isopropanol, respectively.  
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The two candidate substances [FL-no: 14.110 and 14.120] (subgroup 5) in this flavouring group 
evaluation are expected to be metabolised to innocuous products. For the remaining 22 candidate 
substances [FL-no: 14.085, 14.088, 14.089, 14.092, 14.093, 14.103, 14.104, 14.105, 14.106, 14.115, 
14.116, 14.117, 14.118, 14.124, 14.125, 14.131, 14.134, 14.135, 14.136, 14.140, 14.143 and 14.150], 
the Panel would expect metabolites such as N-oxides or epoxides, which cannot be anticipated to be 
innocuous products.  
A more detailed description of the metabolism is given in Appendix C. 
6. Application of the Procedure for the Safety Evaluation of Flavouring 
Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 7. 
For the safety evaluation of the 24 candidate substances the Procedure as outlined in Appendix A was 
applied, based on the MSDI approach. The stepwise evaluations of the 24 substances are summarised 
in Table 7. 
Step 1 
Twenty-two of the 24 candidate substances for which the Procedure could be applied are classified 
into structural class II and two candidate substances into structural class III [FL-no: 14.088 and 
14.131] according to the decision tree approach by Cramer et al. (1978). 
Step 2 
Ethyl nicotinate [FL-no: 14.110] and isopropyl nicotinate [FL-no: 14.120] are expected to be 
hydrolysed in vivo to nicotinic acid and ethanol, and to nicotinic acid and isopropanol, respectively. 
Nicotinic acid is a vitamin and accordingly the evaluation of the two candidate substances proceeds 
via the A-side of the Procedure. 
For the remaining 22 candidate substances [FL-no: 14.085, 14.088, 14.089, 14.092, 14.093, 14.103, 
14.104, 14.105, 14.106, 14.115, 14.116, 14.117, 14.118, 14.124, 14.125, 14.131, 14.134, 14.135, 
14.136, 14.140, 14.143 and 14.150] of this flavouring group, metabolites such as N-oxides or epoxides 
are expected. Therefore, for these 22 candidate substances it cannot be anticipated that they will be 
metabolised to innocuous products and accordingly they proceed via the B-side of the Procedure. 
Step A3 
The two candidate substances [FL-no: 14.110 and 14.129] from subgroup 5, evaluated along the A-
side of the Procedure, are both classified in structural class II. The substances have estimated daily per 
capita intakes from use as flavouring substances of 0.013 and 0.0012 µg. These intakes are below the 
threshold of concern of 540 µg/person/day for structural class II and accordingly ethyl nicotinate [FL-
no: 14.110] and isopropyl nicotinate [FL-no: 14.120] are not expected to be of safety concern at the 
estimated level of intake. Tolerable upper intake levels for nicotinic acid and nicotinamide are 10 and 
900 mg/person/day, respectively (SCF, 2002). 
Step B3 
The levels of intake of the remaining 20 candidate substances classified into structural class II were 
estimated to be between 0.0012 and 0.73 µg/capita/day, which are below the threshold of concern of 
540 µg/person/day. The levels of intake of the candidate substances, evaluated through the Procedure, 
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classified into structural class III were estimated to be 0.0012 µg/capita/day each, which is below the 
threshold of concern of 90 µg/person/day. Therefore, these 22 candidate substances, evaluated via the 
B-side, proceed to step B4. 
Step B4 
Subgroup 1: 
For the candidate substance 2-acetyl-5-methylpyrrole [FL-no: 14.085], a NOAEL of 48 mg/kg bw per 
day for the supporting substance 2-acetylpyrrole [FL-no: 14.047] is derived. The estimated daily per 
capita intake of 0.0012 µg for 2-acetyl-5-methylpyrrole [FL-no: 14.085] corresponds to 0.02 ng/kg 
bw/day at a body weight of 60 kg. Thus, a margin of safety of 2.4 x 109 can be calculated. 2-Acetyl-5-
methylpyrrole is accordingly not expected to be of safety concern at the estimated level of intake. 
Subgroup 3: 
In an oral 37 weeks feeding study in rats on indole-3-carbinole, a substance structurally related to the 
two indole derivatives in this FGE, a NOAEL of 50 mg/kg body weight (bw)/day could be derived. 
The combined estimated daily per capita intake of 0.0024 µg for 1-acetylindole [FL-no: 14.088] and 
2-methylindole [FL-no: 14.131] corresponds to 0.04 ng/kg bw/day at a body weight of 60 kg. Thus, a 
margin of safety of 1.3 x 109 can be calculated. 1-Acetylindole [FL-no: 14.088] and 2-methylindole 
[FL-no: 14.131] are accordingly not expected to be of safety concern at the estimated level of intake. 
Subgroup 4: 
A 90 days oral feeding study in rats is available for the supporting substance 2-acetylpyridine [FL-no: 
14.038]. The NOAEL derived is 37 mg/kg bw/day. The MSDI values for the 19 pyridine derivatives in 
this FGE are between 0.012 and 0.21 µg/capita/day. The combined estimated daily per capita intake 
of these 19 derivatives is 1.5 µg corresponding to 0.025 µg/kg bw/day. Thus, a margin of safety of 1.5 
x 106 can be calculated using the NOAEL of 37 mg/kg bw/day. The 19 pyridine derivatives in this 
flavouring group are accordingly not expected to be of safety concern at the estimated level of intake. 
7. Comparison of the Intake Estimations Based on the MSDI Approach and the 
mTAMDI Approach 
The mTAMDI values are 400 µg/person/day for each of the 24 candidate substances. Twenty-two 
candidate substances are from structural class II and two are from structural class III. These intake 
estimates are above the threshold of concern for the structural class III substances of 90 
µg/person/day. For comparison of the MSDI- and mTAMDI-values see Table 6. 
Thus, for two candidate substances [FL-no: 14.088 and 14.131], further information is required. This 
would include more reliable intake data, and if required, additional toxicological data. 
Table 6:  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(g/capita/day) 
mTAMDI 
(g/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
14.110 Ethyl nicotinate 0.013 400 Class II 540 
14.120 Isopropyl nicotinate 0.0012 400 Class II 540 
14.085 2-Acetyl-5-methylpyrrole 0.0012 400 Class II 540 
14.089 4-Acetylpyridine 0.0073 400 Class II 540 
14.092 2-Butylpyridine 0.012 400 Class II 540 
14.093 3-Butylpyridine 0.061 400 Class II 540 
14.103 2,3-Dimethylpyridine 0.037 400 Class II 540 
14.104 2,4-Dimethylpyridine 0.024 400 Class II 540 
14.105 3,4-Dimethylpyridine 0.13 400 Class II 540 
14.106 3,5-Dimethylpyridine 0.073 400 Class II 540 
14.115 2-Ethylpyridine 0.027 400 Class II 540 
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14.116 4-Ethylpyridine 0.027 400 Class II 540 
14.117 2-Hexylpyridine 0.012 400 Class II 540 
14.118 2-Hydroxypyridine 0.024 400 Class II 540 
14.124 2-Isopropylpyridine 0.021 400 Class II 540 
14.125 4-Isopropylpyridine 0.012 400 Class II 540 
14.134 2-Methylpyridine 0.21 400 Class II 540 
14.135 3-Methylpyridine 0.027 400 Class II 540 
14.136 4-Methylpyridine 0.73 400 Class II 540 
14.140 3-Pentylpyridine 0.0012 400 Class II 540 
14.143 3-Propylpyridine 0.0012 400 Class II 540 
14.150 2,4,6-Trimethylpyridine 0.012 400 Class II 540 
14.088 1-Acetylindole 0.0012 400 Class III 90 
14.131 2-Methylindole 0.0012 400 Class III 90 
8. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2004c; Flavour Industry, 
2005), the combined estimated daily per capita intake as flavourings of the 22 candidate substances 
assigned to structural class II is 1.5 µg, which does not exceed the threshold of concern for a 
compound belonging to structural class II of 540 µg/person/day. The combined daily per capita intake 
as flavourings of the two candidate substances assigned to structural class III and evaluated using the 
Procedure is 0.0024 µg, which does not exceed the threshold of concern for a compound belonging to 
structural class III of 90 µg/person/day.  
The 24 candidate substances, to which the Procedure has been applied, are structurally related to 15 
supporting substances evaluated by JECFA at its 63rd meeting (JECFA, 2006). Based on reported 
production volumes, European per capita intakes (MSDI) could be estimated for all 15 supporting 
substances. The total combined intakes of the candidate and supporting substances are approximately 
90 and 0.0085 µg/capita/day for structural class II and III, respectively, which do not exceed the 
thresholds of concern for a compound belonging to structural class II of 540 µg/person/day and 
structural class III of 90 µg/person/day. 
9. Toxicity 
9.1. Acute Toxicity 
Data are available for four candidate substances and for eight structurally related substances of which 
seven have been evaluated by the JECFA (JECFA, 2006) (supporting substances). The structurally 
related 2,5-dimethylpyrrole [former FL-no: 15.107] is no longer supported by Industry (See Section 
1). The LD50 values range from 60 to 3500 mg/kg body weight (bw).  
The acute toxicity data are summarised in Table 10.  
9.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
No data are available on subacute or subchronic oral toxicity on the candidate substances. Data on 
subacute or subchronic oral toxicity are available for three supporting substances, indole [FL-no: 
14.007], 2-acetylpyridine [FL-no: 14.038], 2-acetylpyrrole [FL-no: 14.047], and the structurally 
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related indole-3-carbinol. For the supporting substance [FL-no: 14.007], there are data on chronic 
toxicity and carcinogenicity.  
Indole-3-carbinol (subgroup 3) 
In two studies, indole-3-carbinole was administered in the feed to male rats (8 animals/group) for 29 
or 37 weeks at doses of 0 and 50 mg/kg bw/day. All tissues and gross lesions were subjected to 
histological examination and body and liver weights were measured. No differences between the 
groups of treated and control animals were detected. The only dose of 50 mg/kg bw has been taken as 
a NOAEL (Tanaka et al., 1990; Tanaka et al., 1992). 
2-Acetylpyridine [FL-no: 14.038] (subgroup 4) 
2-Acetylpyridine was administered to male and female rats (10 animals/sex/group) by gavage for 91 
days at doses of 0, 37, 110, 330 and 1000 mg/kg bw/day. Urine analysis, haematological and 
histological examinations were performed. Liver enlargement was observed in the two highest dosed 
groups. Slight anaemia was observed in females dosed with 110 mg/kg bw and in males dosed with 
330 mg/kg bw. The NOAEL derived was 37 mg/kg bw/day (Til and van der Meulen, 1971). 
2-Acetylpyrrole [FL-no: 14.047] (subgroup 1) 
2-Acetylpyrrole was administered to male and female rats (10 animals/sex/group) by gavage for 91 
days at doses of 0 (dietary control), 1.050, 2.100 and 4.200 mg/kg feed daily in an OECD Guideline 
408 study. However, the test material was not stable in the diet, and part of it was probably not more 
detected by the extraction method employed due to complexation with metal ions in the feed. Bauter 
(2012) calculated that over the course of the study the animals received concentrations of 35 - 40 % of 
the target intake level on average. Therefore, values for exposure levels based on the measured intake 
are proportionally lower. Based on this analysis of the test diets, the mean dietary concentrations were 
calculated to be 367, 754 and 1705 mg/kg feed. These dietary concentrations correspond to average 
daily intakes of 24, 48 and 107 mg/kg bw for males and 28, 56 and 121 mg/kg bw for females, 
respectively, over 90 days. Haematological and histological examinations were performed. Female rats 
of the high intake groups displayed minimal to moderate dark bilateral thyroid glands. Microscopic 
changes of note were slight thyroid hypertrophy/hyperplasia among 4/10 and 10/10 high intake group 
males and females, respectively (Bauter, 2012). However, statistically significantly decreased total 
white blood cell counts, erythrocyte counts, haemoglobin concentrations, haematocrit, absolute 
lymphocyte counts, absolute monocyte counts and absolute basophil counts and increased red cell 
distribution width were reported in the high intake group females on day 86. These parameters are 
outside of historical control levels although the variation are low in magnitude. The thyroid effects at 
the exposure level are of concern, as well as haematological changes in the high dose females. 
Therefore, the NOAEL for 2-acetylpyrrole is derived from the middle dose 48 mg/kg bw/day in males 
and 56 mg/kg bw/day in females. The NOAEL value of 48 mg/kg bw per day was used in calculating 
the margin of safety. The fact that this value is based on calculated lower exposure levels rather than 
the higher levels of 2-acetylpyrrole added to the diet results in a NOAEL level which is on the safe 
side because the effects observed at and ascribed to the lower exposure level, in fact may be due to a 
higher exposure if the loss of 2-acetylpyrrole is less than measured. 
Repeated dose toxicity data are summarised in Table 11. 
9.3. Developmental / Reproductive Toxicity Studies 
There are no data available on developmental or reproductive toxicity for the candidate or the 
supporting substances. 
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9.4. Genotoxicity Studies 
Genotoxicity data were provided for seven of the 24 candidate substances. In in vitro studies on the 
candidate substances 2-methylindole [FL-no: 14.131], 2-methylpyridine [FL-no: 14.134], 3-
methylpyridine [FL-no: 14.135], 4-methylpyridine [FL-no: 14.136], 2,4-dimethylpyridine [FL-no: 
14.104], 3,5-dimethylpyridine [FL-no: 14.106] and 4-acetylpyridine [FL-no: 14.089] in doses up to 
10000 µg/plate, with and without metabolic activation, did not cause reverse mutations in various 
strains of S. typhimurium (Table 12).  
Studies on induction of aneuploidy in S. cerevisiae D61.M are available on the three candidate 
substances 2-methylpyridine [FL-no: 14.134], 2,4-dimethylpyridine [FL-no: 14.104] and 4-
acetylpyridine [FL-no: 14.089] gave positive results. The positive results were obtained at high doses 
inhibiting the growth of the yeast. Furthermore, fungal systems for measuring aneuploidy have little 
relevance compared to the mammalian system. 
No in vivo studies on genotoxicity of the candidate substances were available. 
Genotoxicity tests are available for the eight supporting substances [FL-no: 14.004, 14.007, 14.038, 
14.039, 14.041, 14.047, 14.061 and 14.065]. 2-Acetylpyrrole [FL-no: 14.047] (methyl 2-pyrrolyl 
ketone) was positive in TA98 without metabolic activation at the two highest concentrations. Negative 
results were obtained at the lowest concentration as well as with metabolic activation. This study is 
considered of limited relevance. Pyrrole [FL-no: 14.041], indole [FL-no: 14.007], 3-methylindole [FL-
no: 14.004] (skatole), 3-ethylpyridine [FL-no: 14.061] and 2-acetylpyridine [FL-no: 14.038] gave 
negative results in bacterial mutation assays. 
Studies on induction of aneuploidy in S. cerevisiae D61.M are available on three supporting 
substances, 2,6-dimethylpyridine [FL-no: 14.065], 2-acetylpyridine [FL-no: 14.038] and 3-
acetylpyridine [FL-no: 14.039], which gave positive results. However, as for the three candidate 
substances, the positive results were obtained at high doses inhibiting the growth of the yeast. 
Furthermore, fungal systems for measuring aneuploidy have little relevance compared to the 
mammalian system. 
 
In vivo data are available for one supporting substance. 
3-Methylindole (skatole) [FL-no: 14.004] was reported negative in the micronucleus test in mice. The 
validity of this study, however, cannot be evaluated, as only an abstract is available.  
Positive results were obtained for some candidate and supporting substances in the Rec, DNA 
breaking, CHO and DNA synthesis assays. These results are, however, not considered valid (Table 
12). 
Conclusion on genotoxicity 
The genotoxicity data available for the candidate substances do not preclude their evaluation through 
the Procedure. 
Data on genotoxicity are summarised in Table 12 and 13. 
CONCLUSIONS 
The present Flavouring Group Evaluation deals with 24 pyridine, pyrrole, indole and quinoline 
derivatives. Since the publication of the previous version of FGE.24, FGE.24Rev1, nine of the original 
33 candidate substances [FL-no: 13.100, 14.002, 14.023, 14.094, 14.107, 14.138, 14.145, 14.163 and 
14.169], for which additional data were required, are no longer supported by Industry for use as 
flavouring substances in Europe and will therefore not be considered any further. This revision of 
FGE.24, FGE.24Rev2, therefore only deals with 24 candidate substances. 
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Further, the present revision of FGE.24, FGE.24Rev2, includes the assessment of new toxicity data on 
one supporting substance, 2-acetylpyrrole [FL-no: 14.047], to cover the re-evaluation of one candidate 
substance, 2-acetyl-5-methylpyrrole [FL-no: 14.085], for which additional data were required. 
None of the 24 candidate substances can exist as geometrical or optical isomers. 
Twenty-two of the candidate substances are classified into structural class II and two are classified 
into structural class III. 
Twenty-one of the candidate substances in the present group have been reported to occur naturally in a 
wide range of food items. 
According to the default MSDI approach, the 24 candidate substances in this group have intakes in 
Europe from 0.0012 to 0.73 µg/capita/day, which are all below the thresholds of concern for both 
structural class II (540 µg/person/day) and structural class III (90 µg/person/day) substances. 
On the basis of the reported annual production volumes in Europe (MSDI approach), the total 
combined intakes of the candidate and supporting substances are approximately 90 and 0.0085 
µg/capita/day for structural class II and III, respectively, which do not exceed the thresholds of 
concern for a compound belonging to structural class II of 540 µg/person/day and structural class III 
of 90 µg/person/day, respectively. 
The genotoxicity data available for the candidate substances do not preclude their evaluation through 
the Procedure. 
Two of the 24 candidate substances evaluated through the Procedure, ethyl nicotinate [FL-no: 14.110] 
and isopropyl nicotinate [FL-no: 14.120], are expected to be metabolised to innocuous products. For 
the remaining 22 candidate substances it cannot be anticipated that they will be metabolised to 
innocuous products.  
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure.  
It was considered that, on the basis of the default MSDI approach, the 24 substances, to which the 
Procedure was applied, would not give rise to safety concerns at the estimated levels of intake arising 
from their use as flavouring substances. 
When the estimated intakes were based on the mTAMDI approach they were 400 µg/person/day for 
each of the 22 candidate substances from structural class II, which is below the threshold of concern 
for structural class II of 540 µg/person/day. For the two flavouring substances [FL-no: 14.088 and 
14.131] assigned to structural class III, the estimated intakes based on the mTAMDI are 400 
µg/person/day each. This is above the threshold of concern for structural class III of 90 µg/person/day. 
For the two candidate substances 1-acetylindole [FL-no: 14.088] and 2-methylindole [FL-no: 14.131], 
the intakes, estimated on the basis of the mTAMDI, exceed the threshold for the structural class to 
which the flavouring substance has been assigned. Therefore, for these substances more reliable 
exposure data are required. On the basis of such additional data, these flavouring substances should be 
reconsidered along the steps of the Procedure. Following this procedure additional toxicological data 
might become necessary. 
In order to determine whether the conclusion for the 24 candidate substances could be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity tests for the materials of commerce have been provided 
for all 24 candidate substances.  
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Based on the available data, the Panel concluded that the 24 candidate substances [FL-no: 14.085, 
14.088, 14.089, 14.092, 14.093, 14.103, 14.104, 14.105, 14.106, 14.110, 14.115, 14.116, 14.117, 
14.118, 14.120, 14.124, 14.125, 14.131, 14.134, 14.135, 14.136, 14.140, 14.143 and 14.150]  
evaluated through the Procedure would present no safety concern at the estimated levels of intake 
based on the MSDI approach. 
Flavouring Group Evaluation 24, Revision 2 
 
EFSA Journal 2013;11(11):3453 24 
 
SUMMARY OF SAFETY EVALUATION 
Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
14.110 
 
Ethyl nicotinate 
N
O
O
 
0.013 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.120 
 
Isopropyl nicotinate 
N
O
O
 
0.0012 
 
Class II 
A3: Intake below threshold 
4) 6)  
14.023 
 
1-Methylpyrrole 
N
 
0.3 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required  a) 
14.085 
 
2-Acetyl-5-methylpyrrole 
H
N
O
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.089 
 
4-Acetylpyridine 
N
O  
0.0073 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.092 
 
2-Butylpyridine 
N
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.093 
 
3-Butylpyridine 
N
 
0.061 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.103 
 
2,3-Dimethylpyridine 
N
 
0.037 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.104 
2151 
2,4-Dimethylpyridine 
N
 
0.024 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.105 
 
3,4-Dimethylpyridine 
N
 
0.13 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.106 
 
3,5-Dimethylpyridine 
N
 
0.073 
 
Class II 
B3: Intake below threshold, 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
B4: Adequate NOAEL exists 
14.107 
 
2,5-Dimethylpyrrole 
H
N
 
0.061 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required  a) 
14.115 
 
2-Ethylpyridine 
N
 
0.027 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.116 
 
4-Ethylpyridine 
N
 
0.027 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.117 
 
2-Hexylpyridine 
N
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.118 
 
2-Hydroxypyridine 
N OH
 
0.024 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.124 
 
2-Isopropylpyridine 
N
 
0.021 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.125 
 
4-Isopropylpyridine 
N
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.134 
 
2-Methylpyridine 
N
 
0.21 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.135 
 
3-Methylpyridine 
N
 
0.027 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.136 
 
4-Methylpyridine 
N
 
0.73 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.140 
 
3-Pentylpyridine 
N
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.143 
 
3-Propylpyridine 
N
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
14.145 
 
Pyrrole-2-carbaldehyde 
H
N
O
 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required  b) 
14.150 
 
2,4,6-Trimethylpyridine 
N
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.169 
2150 
1-Ethyl-2-
pyrrolecarboxaldehyde N
O
 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required  b) 
13.100 
 
2-Acetyl-1-furfurylpyrrole 
N
O
O
 
0.091 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required  a) 
14.088 
 
1-Acetylindole 
N
O
 
0.0012 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.131 
 
2-Methylindole 
H
N
 
0.0012 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
14.163 
2152 
1-Methylpyrrole-2-
carboxaldehyde 
N
O
 
0.0024 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required  b) 
14.002 
 
4-Methylquinoline 
N
 
0.12 
 
Class III 
No evaluation 
  a) 
14.094 
 
4-Butylquinoline 
N
 
0.0012 
 
Class III 
No evaluation 
  a) 
14.138 
 
2-Methylquinoline 
N
 
0.012 
 
Class III 
No evaluation 
  a) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
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4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on  
 stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) No longer supported by Industry (EFSA, 2011). 
b) No longer supported by Industry (DG SANCO, 2013). 
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EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 8:  Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 Nicotinic acid N
OH
O  
Not evaluated as flavouring substance  Not in EU-Register. 
02.078 Ethanol 
41 
OH  Category 1 a) 
No safety concern b) 
 
 
 
No evaluation 
At the forty-sixth JECFA meeting (JECFA, 1997), the 
Committee concluded that ethanol posed no safety 
concern at its current level of intake when ethyl esters 
are used as flavouring agents. 
02.079 Isopropanol 
277 
OH
 
Category 1 a) 
No safety concern c) 
 
 
Class I 
A3: Intake above threshold, 
A4: Endogenous 
 
08.002 Acetic acid 
81 
O
OH  
Category 1 a) 
No safety concern d) 
Category A e) 
 
Class I 
A3: Intake above threshold, 
A4: Endogenous 
 
14.007 Indole 
1301 
H
N
 
 
No safety concern f) 
Category A e) 
 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (SCF, 1995). 
b) (JECFA, 1997). 
c) (JECFA, 2000). 
d) (JECFA, 1999). 
e) (CoE, 1992). 
f) (JECFA, 2005b). 
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SUPPORTING SUBSTANCES SUMMARY 
Table 9:  Supporting Substances Summary  
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 1) 
(g/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
 Indole-3-carbinol 
H
N
OH  
 
 
700-06-1 
   Not in EU-Register. 
14.004 3-Methylindole 
H
N
 
3019 
493 
83-34-1 
1304 
JECFA specification 
(JECFA, 2005a). 
2.4  
No safety concern a) 
Category B b) 
 
14.007 Indole 
H
N
 
2593 
560 
120-72-9 
1301 
JECFA specification 
(JECFA, 2005a). 
26  
No safety concern a) 
Category A b) 
 
14.038 2-Acetylpyridine 
N
O
 
3251 
2315 
1122-62-9 
1309 
JECFA specification 
(JECFA, 2005a). 
50  
No safety concern a) 
Category B b) 
 
14.039 3-Acetylpyridine 
N
O  
3424 
2316 
350-03-8 
1316 
JECFA specification 
(JECFA, 2005a). 
23  
No safety concern a) 
Category B b) 
 
14.041 Pyrrole 
H
N
 
3386 
2318 
109-97-7 
1314 
JECFA specification 
(JECFA, 2005a). 
0.11  
No safety concern a) 
Category B b) 
 
14.047 2-Acetylpyrrole H
N
O
 
3202 
11721 
1072-83-9 
1307 
JECFA specification 
(JECFA, 2005a). 
3.3  
No safety concern a) 
 
 
14.058 2-Isobutylpyridine 
N
 
3370 
11395 
6304-24-1 
1311 
JECFA specification 
(JECFA, 2005a). 
0.0061  
No safety concern a) 
 
 
14.059 3-Isobutylpyridine 
N
 
3371 
11396 
14159-61-6 
1312 
JECFA specification 
(JECFA, 2005a). 
0.049  
No safety concern a) 
 
 
14.060 2-Pentylpyridine 
N
 
3383 
11412 
2294-76-0 
1313 
JECFA specification 
(JECFA, 2005a). 
0.061  
No safety concern a) 
 
 
14.061 3-Ethylpyridine 
N
 
3394 
11386 
536-78-7 
1315 
JECFA specification 
(JECFA, 2005a). 
9.3  
No safety concern a) 
 
 
14.065 2,6-Dimethylpyridine 
N
 
3540 
11381 
108-48-5 
1317 
JECFA specification 
(JECFA, 2005a). 
0.26  
No safety concern a) 
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Table 9:  Supporting Substances Summary  
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 1) 
(g/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
14.066 5-Ethyl-2-methylpyridine 
N
 
3546 
11385 
104-90-5 
1318 
JECFA specification 
(JECFA, 2005a). 
0.12  
No safety concern a) 
 
 
14.068 2-Propionylpyrrole H
N
O
 
3614 
11942 
1073-26-3 
1319 
JECFA specification 
(JECFA, 2005a). 
0.012  
No safety concern a) 
 
 
14.071 Methyl nicotinate 
N
O
O  
3709 
 
93-60-7 
1320 
JECFA specification 
(JECFA, 2005a). 
0.49  
No safety concern a) 
 
 
14.164 2-Propylpyridine 
N
 
 
 
622-39-9 
1322 
JECFA specification 
(JECFA, 2005a). 
0.61  
No safety concern a) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2005b). 
b) (CoE, 1992). 
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TOXICITY DATA 
Table 10:  Acute Toxicity 
Chemical Name [FL-no]* Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(2,5-Dimethylpyrrole [14.107], no longer supported)  Rat M, F Oral 59 (Burdock and Ford, 1990)  
(Indole [14.007]) Rat M Oral 1000 (Smyth et al., 1962)  
(3-Methylindole [14.004]) Rat NR Oral 3450 (McGee Laboratories Inc., 1974)  
(2-Propionylpyrrole [14.068]) Mouse M, F Oral 1620 (Moran et al., 1980)  
2-Methylpyridine [14.134] Rat M Oral > 9501 (Dow Chemical Company, 1976)  
Rat NR Oral 400 – 800 (Eastman Kodak Co., 1980)  
Rat NR Oral 1410 (Smyth et al., 1951)  
Rat NR Oral > 500 and < 10002 (Taylor and Olson, 1964)  
Rat M, F Oral 810 (Birch, 1972a)  
Mouse NR Oral 400 – 800 (Eastman Kodak Co., 1980)  
3-Methylpyridine [14.135] Rat M, F Oral 710 (Birch, 1972b)  
Rat M Oral 630 (Dow Chemical Company, 1983)  
4-Methylpyridine [14.136] Rat F Oral 841 (Pullin et al., 1973)  
Rat M, F Oral 700 (Birch, 1972c)  
Rat NR Oral 1290 (Goe, 1984)  
(5-Ethyl-2-methylpyridine [14.066]) Rat NR Oral 1540 (Smyth et al., 1951)  
Rat NR Oral 368 (Izmerov et al., 1982)  
Rat M Oral 1.30 ml/kg (1195) (Myers and Ballantyne, 1997)  
Mouse NR Oral 282 (Izmerov et al., 1982)  
2,4,6-Trimethylpyridine [14.150] Rat M Oral >1000 (Dow Chemical Company, 1985)  
(2-Acetylpyridine [14.038]) Rat NR Oral 2280 (Posternak et al., 1975)  
Rat M, F Oral 2.0 ml/kg (2160) (Spanjers and Til, 1968)  
(3-Acetylpyridine [14.039]) Rat M, F Oral M: 0.052 ml/kg (57) 
F: 0.046 ml/kg (51) 
(Costello et al., 1992)  
(Methyl nicotinate [14.071]) Mouse NR Oral 28003 (Pellmont, 1977)  
*  Supporting substances are listed in brackets. 
1 LD50 not determined. Animals were dosed once and monitored for 28 days following dose administration. At 950 mg/kg bw, 4/10 animals were found dead indicating that the
 LD50 for 2-methylpyridine is slightly 
greater than 950 mg/kg bw.  
2 LD50 not determined. At 500 mg/kg bw, 2/2 animals survived, while at 1000 mg/kg bw 2/2 animals died.
 
3 Administered as a 16 % solution in 5 % gum Arabic. 
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Table 11:  Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]* Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(Indole [14.007]) Rat; M 
6 
Diet 0, 0.25, 0.50 and 
0.75 %  
(~ 0, 138, 275 and 
413 mg/kg 
bw/day) 
21 days < 125 (Martinez and Roe, 1972) Old study with limited quality. Reduced body 
weight at the lowest dose tested, and reduced food 
intake at the two highest doses. No effect on liver 
weight. 
Rat; M, F  
25 (20 F, 5 M) 
Diet 100 mg/kg 
bw/day first 460 
days, then 200 
mg/kg bw/day 
590 days No NOAEL derived (Kaiser, 1953) Dose increased in the end of the study, and 
adverse effects at the lowest dose tested, shown 
by reduced weight, and erythrocyte count, and 
increased leukocyte count. 
(Indole-3-carbinol1) Rat; F 
20 
Diet 0 and 2000 ppm 
(0 and 100 mg/kg 
bw/day) 
25 weeks No NOAEL derived (Stoner et al., 2002) Non-GLP study of reasonable quality. Indole-3-
carbinol significantly increased liver foci 
development compared to control and reduced 
body weight gain.  
Rat; F 
10 
Gavage 5, 25, 50, 100 and 
200 mg/kg 
bw/day 
6 weeks 100 (Grubbs et al., 1995) Published non-GLP study of limited quality. 200 
mg/kg bw gave a 20 % increase in liver weight. 
Additionally 100 days (14 weeks) study with 100 
mg/kg bw indole-3-carbinol increased liver 
weight by 33 %. Experimental details and results 
insufficiently reported. 
Rat; M 
8 
 
Diet 0 and 1000 ppm 
(0 and 50 mg/kg 
bw/day) 
37 weeks  50 (Tanaka et al., 1992) Study of neoplastic lesions in oral cavity, 
especially the tongue. Histological examination 
performed on all major tissues. No effect on body 
weight, liver weight or neoplasm in tongue or 
liver. Reasonable quality. 
0 and 1000 ppm 
(0 and 50 mg/kg 
bw/day) for seven 
weeks 
29 weeks 50 (Tanaka et al., 1990) Published non-GLP study of reasonable quality. 
Histological examination. Study on liver 
carcinogenesis. No effect of indole-3-carbinol. 
(2-Acetylpyrrole [14.047]) Rat; M, F 
32 
Diet 0, 87 (M) and 86 
(F) mg/kg bw/day 
91 days M: 87.462 
F: 86.312 
(Posternak et al., 1975) Haematological examination. Histological 
examination and weight of liver and kidney.  
Slightly reduction in body weight gain in males. 
Poorly reported study and it can therefore not be 
used in the Procedure. 
 Rat; M, F 
10 
Diet 0, 68, 133 and 263 
mg/kg bw for 
males 
0, 79, 155 and 298 
mg/kg bw for 
females 
91 days M: 48  
F: 56  
(Bauter, 2012) OECD Guideline study (408).  
Test material was not stable in the diet. Bauter 
calculated that over the course of the study the 
animals received only 35 - 40 %. The mean 
dietary concentrations were calculated to be 367, 
754 and 1705 mg/kg feed. These dietary 
concentrations correspond to average daily intakes 
of 24, 48 and 107 mg/kg bw for males and 28, 56 
and 121 mg/kg bw for females, respectively, over 
90 days. 
(2-Acetylpyridine [14.038]) Rat; M, F 
32 
Diet 0, 3.13 (M) and 
3.06 (F) mg/kg 
91 days M: 3.132 
F: 3.062 
(Posternak et al., 1975) Haematological examination. Histological 
examination and weight of liver and kidney.  No 
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Table 11:  Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]* Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
bw/day significant effect. Poorly reported study and it can 
therefore not be used in the Procedure. 
Rat; M, F 
20 
Gavage 0, 37, 110, 330 
and 1000 mg/kg 
bw/day six days a 
week 
91 days 37 (Til and van der Meulen, 
1971) 
Old study of reasonable quality. Urine, 
haematological and histological examination. 
Liver enlargement in the two highest dosage 
groups. Slight anaemia in females from 110 
mg/kg bw and in males from 330 mg/kg bw. 
*  Supporting substances are listed in brackets. 
1 Major metabolite of 3-methylindole (skatole).  
2 Study performed with either a single dose level or multiple dose levels that produced no adverse effect.   
3 Study performed with a single dose level that produced no adverse effect. This study was conducted to determine if 6-methylquinoline induced lesions or tumours similar to structurally-related substances. 6-
Methylquinoline did not induce a statistically significant quantity of lesions or tumours in the rat when administered via the diet at 0.05 %.       
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Developmental and reproductive toxicity data are not available neither for the candidate substances of the present flavouring group evaluation from chemical 
group 28, nor for the supporting substance evaluated by JECFA at the 63rd meeting. 
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Table 12:  Genotoxicity (In Vitro) 
Chemical Name [FL-no]* Test System Test Object Concentration 
 
Result Reference Comments 
(Pyrrole [14.041]) Ames assay  
(modified pre-incubation 
method) 
S. typhimurium  
TA98; TA100; TA102 
1.4 mmol/plate 
(93926 µg/plate) 
Negative1 (Aeschbacher et al., 1989)   
Ames assay  
(pre-incubation method) 
S. typhimurium  
TA100; TA1535; TA1537 
3 µmol/plate  
(201 µg/plate) 
Negative1 (Florin et al., 1980)   
Ames assay  
(pre-incubation method) 
S. typhimurium  
TA98 
30 µmol/plate 
(2013 µg/plate)  
Negative1   
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Not reported Negative3 (Lee et al., 1994)   
Rec assay B. subtilis 
H17 (rec+), M45 (rec-) 
4 and 20 mg/disk Positive3 (Kim et al., 1987) Poor predictive value for 
mutagenicity. Limited value. 
Unscheduled DNA 
synthesis 
Rat hepatocytes Not reported Negative (Williams, 1984)  
(Indole [14.007]) Ames assay  
(pre-incubation method) 
S. typhimurium 
TA100 
20 µg/plate Negative2 (Ochiai et al., 1986)  
Ames assay S. typhimurium 
TM677 
4 mM 
(469 µg/ml) 
Negative3 (Kaden et al., 1979)  
Ames assay  
(plate incorporation 
method) 
S. typhimurium TA98; TA100; TA1535; 
TA1538 
2500 µg/plate Negative1 (Anderson and Styles, 1978)  
Ames assay S. typhimurium 
TA98; TA100 
500 nmol/plate 
(59 µg/plate) 
Negative2 (Vance et al., 1986)  
Ames assay  
(pre-incubation method) 
S. typhimurium 
TA100; TA1535; TA1537 
3 µmol/plate 
(351 µg/plate) 
Negative1 (Florin et al., 1980)  
S. typhimurium 
TA98 
30 µmol/plate 
(3515 µg/plate) 
Negative3  
S. typhimurium 
TA97; TA102 
1000 µg/plate Negative1 (Fujita et al., 1994)  
S. typhimurium TA98; TA100 
E. coli WP2uvrA/ pKM101 
0.4 µmol/plate 
(47 µg/plate) 
Negative1 (Sasagawa and Matsushima, 
1991) 
 
S. typhimurium 
TA100 
500 µg/plate Negative2 (Hashizume et al., 1991)  
2-Methylindole [14.131] Ames assay  
(pre-incubation method) 
S. typhimurium 
TA98; TA100; TA1535; TA1538 
4, 20, 100, 500 and 2500 
µg/plate 
Negative1 (Anderson and Styles, 1978) The study is considered valid. 
S. typhimurium 
TA98; TA100; TA1535; TA1537 
3 µmol/plate 
(394 µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
Ames assay S. typhimurium 
TA98 
3 nmol - 30 µmol/plate (12 
doses) 
(3935 µg/plate) 
Negative1 (Curvall et al., 1982) The study is considered valid. 
S. typhimurium 
TM677 
2 mM 
(262 µg/ml) 
Negative (Kaden et al., 1979) Single dose study. 
(3-Methylindole [14.004]) Ames assay  
(pre-incubation method) 
S. typhimurium 
TA100; TA1535; TA1537 
3 µmol/plate 
(394 µg/plate) 
Negative1 (Florin et al., 1980)  
S. typhimurium 30 µmol/plate Negative1 (Florin et al., 1980)  
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Table 12:  Genotoxicity (In Vitro) 
Chemical Name [FL-no]* Test System Test Object Concentration 
 
Result Reference Comments 
TA98 (3935 µg/plate) 
Ames assay S. typhimurium 
TA98; TA100 
Not reported Negative3 (Kim et al., 1989)  
Ames assay  
(pre-incubation method) 
S. typhimurium TA98; TA100 
E. coli WP2uvrA/ pKM101 
0.4 µmol/plate 
(52 µg/plate) 
Negative1 (Sasagawa and Matsushima, 
1991) 
 
S. typhimurium 
TA100 
100 µg/plate Negative2 (Ochiai et al., 1986)  
S. typhimurium 
TA100 
Up to 3.33 mM 
(437 µg/ml) 
Negative3 (Reddy et al., 2002)  
Mutation assay  
(paper-disk method) 
E. coli 
Sd-4-73 
0.025 ml/disk Negative (Szybalski, 1958)  
Chromosomal aberration 
assay 
Chinese hamster 
ovary cells 
1.3, 1.4, 1.5 mM (+ S9) 
1.4, 1.5, 1.6 mM (- S9) 
Positive1 (Reddy et al., 2002) Aberrations were only detected 
at cytotoxic concentrations that 
showed marked inhibition of 
DNA synthesis. 
Alkaline elution assay Rat primary hepatocytes (unindiced and 
PB/-NF induced) 
0.5, 0.6, 0.7, 0.8, 0.9 and 1 
mM 
Negative (Reddy et al., 2002) The study is considered valid. 
DNA modification assay Isolated human genomic DNA 25 and 500 µM (66 µg/ml) Positive3 
Negative2 
(Laws et al., 2001) Assay demonstrating inhibition 
of PCR amplification and spots 
demonstrated by postlabeling. 
Limited predictive value. 
DNA Single strand break 
assay 
Bovine kidney cells 10 μM - 1 mM 
(131.2 µg/ml) 
Positive (Kim et al., 1989) Abstract only. Validity cannot 
be evaluated. 
(2-Acetylpyrrole [14.047]) Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98 
4, 20 and 100 µmol/plate 
(10913 µg/plate) 
Negative3 
Positive2 
(Lee et al., 1994) 
 
Positive without S9 only at the 
two highest concentrations. 
High concentrations.  
Technically acceptable, but of 
limited relevance due to high 
concentrations. 
S. typhimurium 
TA100 
100 µmol/plate 
(10913 µg/plate) 
Negative1  
Ames assay S. typhimurium 
TA98; TA100 
Up to 200 µg/plate Negative1 (Wang et al., 1994)  
2-Methylpyridine [14.134] Ames assay  
(pre-incubation method) 
S. typhimurium 
TA98; TA100; TA1535; TA1537 
3 µmol/plate 
(279 µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
Ames assay  
(modified pre-incubation 
method) 
S. typhimurium 
TA98; TA100; TA102 
10 nmol - 1 mmol/plate  
(6 doses) 
(93 µg/ml) 
Negative1 (Aeschbacher et al., 1989) The study is considered valid. 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA97; TA98; TA100; TA102 
Up to 5000 µg/plate  
(6 doses) 
Negative1 (Claxton et al., 1987) Individual dose levels not 
reported. The study is 
considered valid. 
S. typhimurium 
TA98; TA100; TA1535; TA1537 
50, 160, 500, 1600 and 
5000 nl/plate  
(4722 µg/plate) 
Negative1 (Vleminckx et al., 1993a) The study is considered valid. 
Mitotic aneuploidy assay S. cerevisiae 
D61.M 
0.5 - 0.74% (6 doses) 
(6988 µg/ml) 
Positive (Zimmermann et al., 1986) Very high doses. The effect is 
considered thresholded. 
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Table 12:  Genotoxicity (In Vitro) 
Chemical Name [FL-no]* Test System Test Object Concentration 
 
Result Reference Comments 
Limited relevance. 
HGPRT Gene mutation 
assay 
Chinese hamster V79 lung cells 4.5, 4.75, 5, 5.25 and 5.5 
µl/ml  
(5194 µg/ml) 
Negative2 (Vleminckx et al., 1993b) The study is considered valid. 
Alkaline elution assay Chinese hamster V79 lung cells 2, 3, 4, 5 and 6 µl/ml  
(5666 µg/ml) 
Negative2 (Schriewer et al., 1993) The study is considered valid. 
3-Methylpyridine [14.135] Ames assay  
(modified pre-incubation 
method)  
S. typhimurium 
TA98; TA100; TA1535; TA1537  
85, 280, 840 and 8540 
µg/plate  
Negative  (Haworth et al., 1983)  The study is considered valid. 
Ames assay  
(plate incorporation 
method)  
S. typhimurium 
TA98; TA100; TA1535; TA1537  
50, 160, 500, 1600 and 
5000 nl/plate  
(4785 µg/plate) 
Negative1 (Vleminckx et al., 1993a) The study is considered valid. 
Mutagenicity assay  E. coli  
WP2 uvrA  
5 - 10 mg/plate  
(5000 – 10,000 µg/plate)   
Negative  (Pai et al., 1978)  Single dose study. Very few 
experimental details. The 
validity cannot be evaluated. 
HGPRT Gene mutation 
assay 
Chinese hamster 
V79 lung cells  
3, 3.25, 3.5, 3.75 and 4 
µl/ml  
(3828 µg/ml) 
Negative2  (Vleminckx et al., 1993b) The study is considered valid. 
Alkaline elution assay  Chinese hamster 
V79 lung cells  
2, 3, 4 and 5 µl/ml  
(4785 µg/ml) 
Negative2 (Schriewer et al., 1993)  The study is considered valid. 
4-Methylpyridine [14.136] Ames assay  
(plate incorporation 
method)  
S. typhimurium 
TA98; TA100; TA1535; TA1537  
50, 160, 500, 1600 and 
5000 nl/plate  
(4779 µg/plate) 
Negative1 (Vleminckx et al., 1993a)  The study is considered valid. 
HGPRT Gene mutation 
assay 
Chinese hamster 
V79 lung cells  
3.75, 4, 4.25 and 4.5 µl/ml  
(4301 µg/ml) 
Negative2 (Vleminckx et al., 1993b)  The study is considered valid. 
Alkaline elution assay  Chinese hamster 
V79 lung cells  
3.75, 4, 4.25 and 4.5 µl/ml  
(4301 µg/ml) 
Negative2 (Schriewer et al., 1993)  The study is considered valid. 
(3-Ethylpyridine [14.061]) Ames assay 
(pre-incubation method) 
S. typhimurium TA98; TA100; TA1535; 
TA1537 
3 µmol/plate  
(321µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
2,4-Dimethylpyridine [14.104] Mitotic aneuploidy assay S. cerevisiae D61.M 0.4 - 0.60% (6 doses) 
(5551µg/ml) 
Positive (Zimmermann et al., 1986) Very high doses. The effect is 
considered thresholded. 
Limited relevance. 
(2,6-Dimethylpyridine [14.065]) Mitotic  
aneuploidy assay 
S. cerevisiae  
D61.M 
0.5 - 0.60% (4 doses) 
(5551 µg/ml) 
Positive (Zimmermann et al., 1986) Very high doses. The effect is 
considered thresholded. 
Limited relevance. 
3,5-Dimethylpyridine [14.106] Ames assay  
(pre-incubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
3 µmol/plate  
(321 µg/plate) 
Negative1 (Florin et al., 1980) Single dose study. 
(2-Acetylpyridine [14.038]) Ames assay  
(plate incorporation 
method) 
S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
100 - 10,000 µg/plate Negative (Longfellow, 1997) Very short summary. The 
results cannot be validated. 
High doses. 
Mouse lymphoma assay Mouse lymphocytes  
L5178Y tk+/– 
2500 - 4500 µg/ml (-S9) 
1000 - 4000 μg/ml(+S9) 
Positive1 Very short summary. The 
results cannot be validated.  
Mitotic aneuploidy assay S. cerevisiae  
D61.M 
0.5 - 0.87%(4 doses) 
(9396 µg/ml) 
Positive (Zimmermann et al., 1986) Very high doses. The effect is 
considered thresholded. 
Limited relevance. 
(3-Acetylpyridine [14.039]) Mutation  E. coli  10000 µg/plate Negative (Pai et al., 1978) Single dose study. Very few 
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Table 12:  Genotoxicity (In Vitro) 
Chemical Name [FL-no]* Test System Test Object Concentration 
 
Result Reference Comments 
WP2uvrA experimental details. The 
validity cannot be evaluated. 
Mitotic aneuploidy assay S. cerevisiae 
D61.M 
0.5 - 1.11% (5 doses) 
(1223 µg/ml) 
Positive (Zimmermann et al., 1986) Very high doses. The effect is 
considered thresholded. 
Limited relevance. 
4-Acetylpyridine [14.089] Ames assay  
(pre-incubation method) 
S. typhimurium 
TA97; TA98; TA100; TA102; TA104; 
TA1535; TA1537; TA1538 
5, 100, 300, 100, 3000 and 
10,000 µg/plate 
Negative1 (Zeiger et al., 1992) The study is considered valid. 
Mitotic aneuploidy assay S. cerevisiae  
D61.M 
0.5 - 1.19% (5 doses) 
(13,114 µg/ml) 
Positive (Zimmermann et al., 1986) Very high doses. The effect is 
considered thresholded. 
Limited relevance. 
Mitotic aneuploidy assay S. cerevisiae 
D61.M 
Up to 11 mg/ml 
 
Positive (Whittaker et al., 1989)  Purity 88 %. Very high doses. 
The effect is considered 
thresholded. Limited relevance. 
*  Supporting substances are listed in brackets. 
1 With and without metabolic activation. 
2 Without metabolic activation. 
3 With metabolic activation. 
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Table 13:  Genotoxicity (In Vivo) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
(3-Methylindole [14.004])* In vivo Micronucleus test Mouse Oral  1000 mg/kg day Negative (Reddy et al., 2003) Abstract only. The validity cannot be evaluated. 
*  Supporting substance. 
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APPENDIX A: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996; JECFA, 1997; JECFA, 1999). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 µg/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
 can the flavourings be predicted to be metabolised to innocuous products11 (Step 2)?  
 do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
 are the flavourings or their metabolites endogenous12 (Step A4)?  
 does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
11 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
```estimated intakes of the flavouring agent” (JECFA, 1997). 
 
12 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
```conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
```(JECFA, 1997). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products? 
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
 
 
  Substance would not be    
expected to be of safety concern 
Is the substance or are its metabolites endogenous? 
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4. 
 Yes  No 
 Yes 
 No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
 No 
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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APPENDIX B: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the 
Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is defined 
as the 95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring 
substances (EFFA, 2004a). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000). 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
V 03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the 24 candidate substances in the 
present flavouring group (Table II.1.2). The table also contains “normal and maximum use levels” for 
the nine substances no longer supported by Industry for use as flavouring substances in Europe: [FL-
no: 13.100, 14.002, 14.023, 14.094, 14.107, 14.138, 14.145, 14.163 and 14.169] (DG SANCO, 2013; 
EFSA, 2011). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.24 (EFFA, 2004b; 
EFFA, 2007; Flavour Industry, 2005). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
13.100 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
14.002 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
14.023 4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.085 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.088 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.089 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.092 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.093 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.094 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.103 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.24 (EFFA, 2004b; 
EFFA, 2007; Flavour Industry, 2005). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
14.104 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.105 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.106 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.107 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.110 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.115 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
- 
- 
0,2 
1 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.116 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.117 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.118 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.120 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.124 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.125 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.131 0,4 
2 
0,2 
1 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.134 0,4 
2 
0,2 
1 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.135 0,4 
2 
0,2 
1 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.136 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.138 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.140 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.143 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.145 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.150 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.163 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,2 
1 
1 
5 
1 
5 
0,2 
1 
14.169 0,6 
1,8 
- 
- 
0,6 
1,8 
- 
- 
- 
- 
1,2 
3,6 
0,6 
1,8 
1,2 
3,6 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0,3 
0,9 
1,2 
3,6 
- 
- 
0,6 
1,8 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table II.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995). 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
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The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour 
Industry in the following way (see Table II.2.2): 
 Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000) 
 Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 
16 (EC, 2000) 
 Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000) 
 Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000) 
 Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000) 
 Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000) 
 Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 
(EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995). 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for each of the 24 flavouring substances in the 
present flavouring group, for which Industry has provided use and use levels (EFFA, 2004b; Flavour 
Industry, 2005; EFFA, 2007). The mTAMDI values are only given for the highest reported normal use 
levels (See Table II.2.3). The table also contains the mTAMDI values for the nine substances no 
longer supported by Industry for use as flavouring substances in Europe: [FL-no: 13.100, 14.002, 
14.023, 14.094, 14.107, 14.138, 14.145, 14.163 and 14.169] (DG SANCO, 2013; EFSA, 2011). 
TableII.2.3 Estimated intakes based on the mTAMDI approach. 
FL-no EU Register name mTAMDI 
(g/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
14.110 Ethyl nicotinate 400 Class II 540 
14.120 Isopropyl nicotinate 400 Class II 540 
14.023 1-Methylpyrrole 670 Class II 540 
14.085 2-Acetyl-5-methylpyrrole 400 Class II 540 
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14.089 4-Acetylpyridine 400 Class II 540 
14.092 2-Butylpyridine 400 Class II 540 
14.093 3-Butylpyridine 400 Class II 540 
14.103 2,3-Dimethylpyridine 400 Class II 540 
14.104 2,4-Dimethylpyridine 400 Class II 540 
14.105 3,4-Dimethylpyridine 400 Class II 540 
14.106 3,5-Dimethylpyridine 400 Class II 540 
14.107 2,5-Dimethylpyrrole 400 Class II 540 
14.115 2-Ethylpyridine 400 Class II 540 
14.116 4-Ethylpyridine 400 Class II 540 
14.117 2-Hexylpyridine 400 Class II 540 
14.118 2-Hydroxypyridine 400 Class II 540 
14.124 2-Isopropylpyridine 400 Class II 540 
14.125 4-Isopropylpyridine 400 Class II 540 
14.134 2-Methylpyridine 400 Class II 540 
14.135 3-Methylpyridine 400 Class II 540 
14.136 4-Methylpyridine 400 Class II 540 
14.140 3-Pentylpyridine 400 Class II 540 
14.143 3-Propylpyridine 400 Class II 540 
14.145 Pyrrole-2-carbaldehyde 400 Class II 540 
14.150 2,4,6-Trimethylpyridine 400 Class II 540 
14.169 1-Ethyl-2-pyrrolecarboxaldehyde 310 Class II 540 
13.100 2-Acetyl-1-furfurylpyrrole 160 Class III 90 
14.088 1-Acetylindole 400 Class III 90 
14.131 2-Methylindole 400 Class III 90 
14.163 1-Methylpyrrole-2-carboxaldehyde 400 Class III 90 
14.002 4-Methylquinoline 160 Class III 90 
14.094 4-Butylquinoline 400 Class III 90 
14.138 2-Methylquinoline 400 Class III 90 
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APPENDIX C: METABOLISM 
III.1. Introduction 
This flavouring group consists of 24 candidate substances, all of which have one heterocyclic N-atom 
in a five- or six-membered ring structure. Twenty-two of the compounds are monocyclic, with either a 
five-membered ring (pyrroles) [FL-no: 14.085] or a six-membered ring (pyridines) [FL-no: 14.089, 
14.092, 14.093, 14.103, 14.104, 14.105, 14.106, 14.110, 14.115, 14.116, 14.117, 14.118, 14.120, 
14.124, 14.125, 14.134, 14.135, 14.136, 14.140, 14.143 and 14.150]. The remaining two candidate 
substances are aromatic bicyclic structures consisting of a six- and a five-membered ring (indoles) 
[FL-no: 14.088 and 14.131]. The substances are substituted with simple alkyl, alcohol, ketone or ester 
moities.  
The candidate substances are divided into four subgroups with similar structural properties as shown 
in Table III.1 (The substances previously allocated to subgroups 2 and 6 are no longer supported by 
Industry (See Section 1)). 
A group with 15 related supporting substances has been evaluated by the JECFA (JECFA, 2006). 
Table III.1 Candidate substances divided into groups of related chemical structures.  
Subgroup Candidate substance FL-no Chemical 
group 
1 2-Acetyl-5-methylpyrrole 14.085  
2 
The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry  
 
N-substituted 
pyrroles 
3 
2-Methylindole 14.131 
Indoles 1-Acetylindole 14.088 
4 
2-Methylpyridine 14.134 
Pyridines with 
alkyl, hydroxyl 
or acetyl  
groups 
3-Methylpyridine 14.135 
4-Methylpyridine 14.136 
2-Ethylpyridine 14.115 
4-Ethylpyridine 14.116 
3-Propylpyridine 14.143 
2-Isopropylpyridine 14.124 
4-Isopropylpyridine 14.125 
2-Butylpyridine 14.092 
3-Butylpyridine 14.093 
3-Pentylpyridine 14.140 
2-Hexylpyridine 14.117 
2,3-Dimethylpyridine 14.103 
2,4-Dimethylpyridine 14.104 
3,4-Dimethylpyridine 14.105 
3,5-Dimethylpyridine 14.106 
2,4,6-Trimethylpyridine 14.150 
2-Hydroxypyridine 14.118 
4-Acetylpyridine 14.089 
5 
Ethyl nicotinate 14.110 Pyridines with 
ester groups Isopropyl nicotinate 14.120 
6 
The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry  
 
Quinolines 
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III.2. Absorption, Distribution and Elimination 
Nicotinic acid resulting from the hydrolysis of isopropyl nicotinate [FL-no: 14.120] and ethyl 
nicotinate [FL-no: 14.110] is absorbed and excreted in humans given an oral dosage of 3000 mg as 
shown by 88 % recovery in urine (time not reported) (Miller et al., 1960). 
Rabbits given subcutaneous injections of 500 mg of pyrrole on alternate days exhibited a rapid 
increase in the urinary elimination of urea nitrogen (40 to 50 % of the pyrrole dose) over the first 24 
hours (Novello, 1927). 
The excretion of indole in rats is fairly rapid with 75 % of the dosage excreted after 24 hours, and 
more than 80 % of the radioactivity recovered from the pooled 48-hour urine of female albino Wistar 
rats given a single oral dose of 64 to 80 mg/kg [2-14C]-indole. Urine, faeces and expired air contained 
80.6, 11.1, and 2.4 %, respectively, of the radioactivity (King et al., 1966).  
Twenty-four male Holtzman rats were administered diets supplemented with 0, 0.25, 0.50 or 0.75 % 
(corresponding to 0, 150, 300 and 450 mg/kg bw/day) indole for three weeks. A fifth group of six rats 
receiving 0.75 % indole was supplemented with 0.25 % methionine in the diet. During week 3, all 
groups (including controls) received a single dose of [2-14C]-indole via stomach tube. Urine collected 
for 72 hours after the single dose administration revealed that 32, 47, 49, 51 and 62 % of the 
radioactive dose were recovered from the 0 (control), 0.25, 0.50, 0.75 % indole groups, and the 0.75 % 
indole plus 0.25 % methionine groups, respectively, demonstrating a slower elimination of indole from 
the body than reported by King et al., 1966 (Martinez and Roe, 1972). 
Mice and rats given single intraperitoneal injections of 400 mg/kg of [14C]-3-methylindole excreted 
69.4 % and 66.2 % of the total radioactivity, respectively, after 48 hours (Skiles et al., 1991). 
In male rats administered a dosage of 100 mg/kg bw of 2,3-dimethylpyridine [FL-no: 14.103] by 
gavage, 50 % of the administered dosage were excreted in the urine after 24 hours (Hawksworth and 
Scheline, 1975). Ninety-six per cent of a 100 mg/kg bw dose of 2-methylpyridine administered via 
gavage to male albino Wistar rats was excreted within 24 hours (Hawksworth and Scheline, 1975). 
More than 50 % of a 300 mg/kg bw dose of 4-methylpyridine, administered to Wistar rats (3/sex) via 
gavage was excreted in the urine after 24 hours (Nguyen et al., 1988). 
Studies with indoles and 2-methyl- and 2,3-dimethyl pyridine indicate that the candidate indoles and 
pyridines are absorbed from the gastrointestinal tract and fairly rapidly excreted in the urine. No data 
on absorption and excretion are available for the candidate pyrroles and quinolines. 
III.3. Biotransformation 
Ester and amide hydrolysis 
Two studies on the hydrolysis of the candidate substances ethyl nicotinate [FL-no: 14.110] and 
isopropyl nicotinate [FL-no: 14.120] are reported. 
Several nicotinates were studied in vitro for their binding to and hydrolysis by human serum albumin. 
After 90 minutes of dialysis, 4.1 and 0 % of ethyl nicotinate and isopropyl nicotinate, respectively, 
were hydrolysed in human serum albumin as compared to 0.1 and 0 % in buffer. The percentage 
bound by human serum albumin was 35.6 and 34.1 % for ethyl nicotinate and isopropyl nicotinate, 
respectively (Steiner et al., 1992). 
In a study of the effect of substrate on the rate of carboxyesterase-catalysed hydrolysis, the steady state 
kinetic constants for a series of nicotinates were determined. Purified hog liver carboxylesterase and 
human plasma containing carboxyesterase were incubated with ethyl nicotinate and isopropyl 
Flavouring Group Evaluation 24, Revision 2 
 
EFSA Journal 2013;11(11):3453 56 
nicotinate. The maximal velocity (Vmax) for ester hydrolysis in purified hog liver carboxyesterase and 
human plasma is 18.4 mmol/min/mg protein and 2.16 µmol/min/mg protein, respectively, for ethyl 
nicotinate and 97.8 mmol/min/mg protein and 0.20 µmol/min/mg protein, respectively, for isopropyl 
nicotinate (Durrer et al., 1992). 
No study on the hydrolysis of the amide bond in the candidate substance 1-acetylindole [FL-no: 
14.088] was reported. Amides are hydrolysed by the same enzymes as the esters, although the 
hydrolysis of amides generally occurs more slowly (Parkinson 1996, Chapter 6 Casarett & Doull’s).  
The hydrolysis of ethyl nicotinate and isopropyl nicotinate in human serum is expected to be relatively 
slow. However, purified hog liver carboxylesterase hydrolyses the same compounds rapidly, which 
might result from the different enzyme concentrations used. A rapid hydrolysis of 1-acetylindole in the 
Gastro-intestinal (GI) tract is not anticipated although hydrolysis by amidases in the tissues might be 
expected. 
Metabolism of pyrroles (subgroup 1) 
Pyrrole is an electron-rich compound, electron density being high at all positions of the ring but 
greatest at C-2 and C-5. It is very reactive toward electrophilic attack at C-2 and resistant to 
nucleophiles. Pyrrole is a likely substrate for electrophilic enzymatic oxidation at N-1 and 
hydroxylation at C-2 and C-5 (Damani and Crooks, 1982). 
No metabolism studies were found for the candidate substance 2-acetyl-5-methylpyrrole [FL-no: 
14.085].  
Metabolism of indoles (subgroup 3) 
No metabolism studies were found for the candidate substances 2-methylindole and 1-acetylindole 
[FL-no: 14.131 and 14.088]. However, for the supporting compounds indole [FL-no: 14.007] and 3-
methylindole (skatole) [FL-no: 14.004] several metabolic studies are available.  
The main metabolite of indole in various species is 3-hydroxylindole (indoxyl) and with the 2-
oxygenated and 5-hydroxylated metabolites oxindole and 5-hydroxyoxindole as minor metabolites 
(Figure III.2) (Damani and Crooks, 1982). 
Ring hydroxylation on both rings of indole compounds has been well documented (Figures III.1 and 
III.2), and indole is very reactive toward electrophilic attack at C-3. Following oral dosing of three 
albino Wistar rats with single doses of 64 to 74 mg/kg bw of [2-14C]-indole, 63 % of the dose was 
detected in 48-hour urine pools as 3-hydroxyindole (indoxyl), as sulphate conjugate (49.6 %) and 
glucuronide conjugate (13.2 %). In two of the rats, other metabolites identified in the urine included 
3.5 % 5-hydroxyoxindole, 1.4 % indole-2-one and 5.8 % indole-2,3-dione (isatin). Analysis of the 
faecal excretions showed 0.14, 0.40, and 0.64 % radiolabel as indole, 3-hydroxyindole sulphate and 
total 3-hydroxyindole metabolites, respectively (King et al., 1966). In a parallel study, 48-hour bile 
samples of two female albino Wistar rats given 49 to 63 mg/kg bw [2-14C]-indole orally, contained 
0.56, 0.80, and 0.82 % of the radiolabel as 5-hydroxyoxindole, 3-hydroxyindole sulphate and total 3-
hydroxyindole metabolites, respectively, as minor metabolites (King et al., 1966). 
Twenty-four male Holtzman rats were administered diets supplemented with 0, 0.25, 0.50 or 0.75 % 
(corresponding to 0, 150, 300 and 450 mg/kg bw/day) indole for three weeks. A fifth group of six rats 
receiving 0.75 % indole was supplemented with 0.25 % methionine in the diet. During week 3, all 
groups (including controls) received a single dose of [2-14C]-indole via stomach tube. Urine collected 
for 72 hours after the single dose administration revealed the two main radioactive metabolites as 3-
indolyl sulphate and 3-indolyl glucuronidate. The amount excreted as glucuronidate was increasing 
with increasing dose of administered indole (Martinez and Roe, 1972) 
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3-Hydroxyindole was the primary metabolite isolated when indole was incubated with freshly 
prepared rabbit liver microsomes (Posner et al., 1961). 3-Hydroxyindole may further be oxidised to 
indigo (2-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,2-dihydro-3H-indol-3-one) (Posner et al., 1961). 
Incubation of indole with rat liver microsomes in the presence of glucose-6-phosphate, nicotinamide, 
and NADPH for one hour demonstrated the formation of ring oxidised metabolites including indigo, 
indirubin (3-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-2H-indol-2-one) and oxindole (1,3-
dihydro-2H-indol-2-one) (King et al., 1966). When indole was incubated with recombinant human 
CYP450 enzymes, 2A6, 2C19, and 2E1 co-expressed in Escherichia coli with NADPH-P450 
reductase, several metabolites was detected. Oxindole was detected as the major metabolite, while 
indole-2,3-dione, 6-hydroxyindole, dioxindole, indigo and indirubin was detected in less amounts. 3-
Hydroxyindole was observed as a transient product (Gillam et al., 2000).  
 
 
Figure III.1. The metabolism of indole in rats (King et al., 1966). Main metabolism product is in bold. 
Mice and rats given single intraperitoneal injections of 400 mg/kg of [methyl-14C]-3-methylindole 
excreted 2.6 and 7.3 %, respectively, as the mercapturic acid conjugate of 3-methylindole, 3-[(N-
acetylcystein-Syl)methyl]indole (Skiles et al., 1991). The mercapturic acid conjugate is likely formed 
via a reactive 3-methylene iminium ion that may be generated either directly via CYP450 mediated 
oxidation of the methyl substituent or indirectly via ready dehydration of indole-3-carbinol (Skiles and 
Yost, 1992). 
At least six metabolites were isolated from the urine 36 hours after male Swiss-Webster mice received 
a 400 mg/kg dose of ring labelled [ring-UL-14C]-3-methylindole by intraperitoneal injection (Figure 
III.2). Three primary pathways were characterised. In one, side chain oxidation yields indole-3-
carbinol. Indole-3-carbinol is then oxidised to the corresponding carboxylic acid. Alternatively, 3-
methylindole can be converted to the reactive substance 3-methyleneindolenine, which subsequently is 
conjugated with glutathione to yield 3-[(N-acetylcystein-S-yl)methyl]indole. In the third pathway, the 
2,3-alkene is epoxidised to yield 3-methyloxindole or 3-hydroxy-3-methylindolenine intermediates. 
These metabolites are conjugated with glucuronic acid or sulphate, followed by excretion in the urine 
or are further oxidised to yield a series of dihydroxy-3-methyloxindole metabolites that are also 
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conjugated and excreted. The second pathway through epoxidation of 3-methylindole predominates 
(Smith et al., 1993). The existence of a cytochrome P450-dependent 2,3-epoxide of 3-methylindole 
was indirectly confirmed using stable isotope techniques and mass spectrometry. After incubation of 
goat lung microsomes with [2-2H]-3-methylindole, metabolically formed 3-methyloxindole was 
produced by NIH shift of the deuterium from position 2 to position 3, a process which is consistent 
with epoxide ring opening (Skordos et al., 1998). 
Incubation of 3-methylindole (0.5 mM) with rabbit Clara cells and alveolar macrophages in 
combination with either N-acetylcystein (NAC) or glutathione (GSH) yielded four metabolites, two 
metabolites derived from side chain oxidation were indole-3-carbinol and the 3-(glutathione-S-
yl)methylindole or 3-(N-acetylcysteine-S-yl)-3-methylindole from incubation with GSH or NAC, 
respectively. The latter two were the major microsomal metabolites. Two other metabolites, 
presumably derived from epoxidation, were 3-methyloxindole and the metabolites from NAC and 
GSH incubation respectively, 2-(N-acetylcystein-S-yl)-3-hydroxy-3-methylindoline and 2-
(glutathione-S-yl)-3-hydroxy-3-methylindoline. Incubation with excess glutathione (4 mM) produced 
the corresponding glutathione conjugates instead of the mercapturic acid conjugates (Thornton-
Manning et al., 1993). Human liver microsomal protein fraction was incubated with labelled [14C]-3-
methylindole in the presence of NADPH. Hydrolysis of the isolated protein fraction indicated the 
presence of a cysteine conjugate at the 3 position of 3-methylindole. The authors suggested that a 
reactive 3-methyleneindolenine intermediate reacts with the cysteine thiol groups of target proteins 
(Ruangyuttikarn et al., 1992). 
 
Figure III.2. Metabolism of 3-methylindole in mice and goat (Skiles et al., 1991; Smith et al., 1993). Main 
metabolism product is in bold. Suggested intermediates are in frame. 
The major pathways of metabolism of 3-methylindole are oxygenation of the double bond in position 
2 and 3 (epoxidation product), dehydrogenation of the methyl group and hydroxylation of the methyl 
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group and the ring structure, leading to metabolites mainly conjugated to glucuronic acid, sulphate and 
glutathione (Figure III.2).  
Mice administered intraperitoneally 0 - 6 mmol/kg bw of L-buthionine-(S,R)sulphoximine (BSO), a 
specific inhibitor of GSH synthesis, three hours prior to treatment with 75 mg/kg bw of [methyl14C]-3-
methylindole, showed a shift in toxicity from the pulmonary tissue to renal tissue. The reduction in 
glutathione level was high in the liver, with 88 % reduction, while the effect in the kidneys and lungs 
was less dramatic with only 38 % and 32 % reduction, respectively. Inhibition with BSO results in the 
lowest level of gluthatione in the kidneys, an organ which will also be affected by reduced 
detoxification by the liver. This shows the importance of glutathione in the detoxification of 3-
methylindole and its metabolites (Yost et al., 1990). 
Metabolism of pyridines 
Electron density calculations show that electrophilic attack in pyridine is favoured at C-3, whereas 
nucleophilic attack occurs preferentially at C-2. The pyridyl nitrogen is a likely target for electrophilic 
enzymatic oxidation because of its relatively high electron negativity and its unshared pairs of 
electrons (Damani and Crooks, 1982). 
Metabolism of pyridines substituted with alkyl groups (subgroup 4) 
There are metabolism studies for four of the candidate pyridines substituted with alkyl groups, 2-
methylpyridine, 3-methylpyridine, 4-methylpyridine and 2,3-dimethylpyridine [FL-no: 14.134, 
14.135, 14.136 and 14.103]. For the rest of the thirteen candidate pyridines substituted with alkyl 
groups no metabolism studies were found (see Table III.1). There are also metabolism studies for the 
supporting substances 3-ethylpyridine [FL-no: 14.061], 3-acetylpyridine [FL-no: 14.039] and 2,6-
dimethylpyridine [FL-no: 14.065], as well as the structurally related 3-hydroxypyridine. 
Ninety-six per cent of a 100 mg/kg bw dose of 2-methylpyridine [FL-no: 14.134] administered via 
gavage to male albino Wistar rats was excreted as the glycine conjugate, pyridine-2-carboxylic acid 
(picolinic acid) within 24 hours. No N-oxidation of 2-methylpyridine was observed with a detection 
limit of the metabolite at 1 % of the dose (Hawksworth and Scheline, 1975).  
Intraperitoneal administration of 40 mg/kg bw of 3-methylpyridine [FL-no: 14.135] to mice, hamsters, 
rats, guinea pigs, or rabbits resulted in the excretion of 6.4, 0.3, 4.0, 0.7 and 0.1 %, respectively, in the 
urine as the corresponding N-oxide within 24 hours (Gorrod and Damani, 1980). 3-Methylpyridine 
was converted to the corresponding N-oxide by fortified hepatic microsomal preparations from 
hamster, guinea-pig, rabbit, rat and mouse, and by pulmonary microsomal preparations from guinea-
pig and rabbit (Cowan et al., 1978). 
More than 50 % of a 300 mg/kg bw dose of 4-methylpyridine [FL-no: 14.136], administered to Wistar 
rats (3/sex) via gavage, was excreted in the urine, principally as pyridine-4-carboxylic acid (50 %) or 
its glycine conjugate (5 %) after 24 hours. Minor metabolites included approximately 5 % unchanged 
4-methylpyridine from expired air and urine and 1.5 % 4-methylpyridine-N-oxide in urine. Two 
metabolic pathways for 4-methylpyridine were confirmed in this study:  
1) N-oxidation leading to the formation of N-oxide and  
2) methyl oxidation leading to the formation of pyridine-4-carboxylic acid (isonicotinic acid) excreted 
mainly unchanged and partly as the glycine conjugate, isonicotinuric acid (Nguyen et al., 1988). 
The supporting substance 3-ethylpyridine [FL-no: 14.061] was converted to the corresponding N-
oxide by fortified hepatic microsomal preparations from hamster, guinea-pig, rabbit, rat and mouse, 
and by pulmonary microsomal preparations from guinea-pig and rabbit (Cowan et al., 1978). 
Flavouring Group Evaluation 24, Revision 2 
 
EFSA Journal 2013;11(11):3453 60 
Three metabolites were detected in rat urine administered a dosage of 100 mg/kg bw of 2,3-
dimethylpyridine [FL-no: 14.103] by gavage corresponding to 50 % of the administered dosage after 
24 hours. The main metabolite was a result of oxidation at the methyl group at the C-3 position, 2-
methylpyridine-3-carboxylic acid (30 % of dose), which was excreted in the urine. In addition, 2,3-
dimethylpyridine was ring hydroxylated at position C-5 and C-6 resulting in the metabolites 2,3-
dimethyl-5-hydroxypyridine and 2,3-dimethyl-6-hydroxypyridine (7 % and 13 % of the dosage). The 
metabolites were excreted in the urine as such and not as glycine conjugate. No urinary N-oxidation 
products were found (with a detection limit of 1 % of the administered compound) (Hawksworth and 
Scheline, 1975). 
For the supporting substance 2,6-dimethylpyridine [FL-no: 14.065], one study on metabolism was 
found. Ninety per cent of a 100 mg/kg bw dose of 2,6-dimethylpyridine administered via gavage to 
male albino Wistar rats was excreted as the glycine conjugate of the 6-methyl-2-carboxylic acid 
(Hawksworth and Scheline, 1975). 
The metabolism of 3-acetylpyridine [FL-no: 14.039] was investigated in dogs after oral (500 mg/kg 
bw every day for eight days) and intraperitoneal (50 mg/kg bw, single dosage) administration. The 
metabolites isolated from urine were 1-(3-pyridyl)ethanol, N-methylated 1-(3-pyridyl)ethanol and (3-
pyridyl)-1,2-ethanediol, which was oxidised to nicotinic acid (McKee et al., 1987) (Figure III.3). 3-
Acetylpyridine was converted to the corresponding N-oxide by fortified hepatic microsomal 
preparations from hamster, guinea-pig, rabbit, rat and mouse, and by pulmonary microsomal 
preparations from guinea-pig and rabbit (Cowan et al., 1978). Similar in vitro results were obtained 
when 3-acetylpyridine was incubated with hepatic supernatant fraction and microsomal fractions from 
rats, guinea pigs, rabbits, hamster and mice, where they identified N-oxide metabolites of both 1-(3-
pyridyl)ethanol and 3-acetylpyridine itself. 1-(3-pyridyl-N-oxide)ethanol is produced by further 
reduction of 3-acetylpyridine-N-oxide, and not from 1-(3-pyridyl)ethanol (Damani et al., 1980).  
In contrast to 3-acetylpyridine, no N-oxidation products of 3-hydroxypyridine were found after 
incubation with liver microsomes from hamster, guinea-pig, rabbit, rat and mouse. (Cowan et al., 
1978).  
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Figure III.3. Metabolism of 3-acetylpyridine in urine from dogs (McKennis et al., 1964) and with microsomal 
preparation from liver of rats, guinea-pigs, rabbits, hamster and mice (in frame)(Damani et al., 1980). Main 
metabolism product in vivo is in bold. 
 
Metabolism of pyridines substituted with ester groups (subgroup 5) 
No metabolism studies were found for the candidate pyridine substances ethyl nicotinate and isopropyl 
nicotinate [FL-no: 14.110 and 14.120].  
However, there are metabolism studies on the hydrolysis product nicotinic acid from hydrolysis of 
ethyl nicotinate and isopropyl nicotinate. No N-oxidation products of nicotinic acid were found after 
incubation with liver microsomes from hamster, guinea-pig, rabbit, rat and mouse (Cowan et al., 
1978). Nicotinic acid is a vitamine metabolite of the nicotinates (Lehninger, 1982). Nicotinic acid 
reacts with 5-phosphoribosyl-1-pyrophosphate to form the nicotinic acid mononucleotide, which then 
condenses with ATP to form the nicotinic acid analogue of nicotinamide adenine dinucleotide (NAD), 
which is subsequently converted to NAD by a reaction with glutamine and ATP. For adults a tolerable 
upper intake level for nicotinic acid of 10 mg/day was established by the Scientific Committee on 
Food in 2000 (SCF, 2000). 
III.4. Summary on metabolism 
Ethyl nicotinate and isopropyl nicotinate [FL-no: 14.110 and 14.120] are expected to be hydrolysed in 
vivo to nicotinic acid and ethanol, and nicotinic acid and isopropanol, respectively. No data are 
available on the hydrolysis of 1-acetylindole [FL-no: 14.088] or supporting substances. Amides are 
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known to be hydrolysed but less rapidly than esters from carboxylic acids. A rapid hydrolysis of 1-
acetylindole is not anticipated due to steric hindrance. 
Subgroup 1: The candidate substance with alkyl substitutions in these positions, 2-acetyl-5-
methylpyrrole [FL-no: 14.085], is more likely hydroxylated on the alkyl group. Further oxidation of 
the acetyl group on 2-acetyl-5-methylpyrrole is also expected. According to (Damani and Crooks, 
1982) pyrroles are likely substrates for elecrophilic enzymatic oxidation at N-1. 
Subgroup 3: The candidate substance 2-methylindole [FL-no: 14.131] and indole, the hydrolysis 
product of 1-acetylindole [FL-no: 14.088], will be metabolised through two main pathways. Oxidation 
of the methyl group in 2-methylindole and in the ring structure, resulting in addition of hydroxyl 
groups which is followed by conjugation to glucuronic acid and sulphate. Secondary epoxidation of 
the double bonds on the pyrrole ring is expected, leading to oxindole compounds which can be further 
oxidised by addition of hydroxyl groups and conjugated with glucuronic acid and sulphate. The 
supporting substance 3-methylindole is metabolised to the reactive metabolite 3-methyleneindolenine 
which is conjugated to GSH. Since a methyleneindolenine is not formed from 2-methylindole, 
conjugation to GSH seems less likely for this substance. The possible metabolic intermediates from 2-
methylindole are probably less reactive than the intermediates formed from 3-methylindole, although 
epoxide intermediates are likely to be formed.  
Subgroup 4: Two main metabolism pathways can be predicted for the alkyl substituted pyridines. The 
main pathway is hydroxylation of the alkyl groups, with additional oxidation to the corresponding 
carboxyl compounds. The carboxyl metabolites are excreted in the urine as such or in conjugation with 
glycine. Alternatively the candidate pyridines may be oxidised on the nitrogen atom, and excreted in 
the urine without conjugation. Hydroxylation of the pyridine ring through epoxide intermediates 
cannot be excluded, although not shown to be a major pathway of the supporting compound. However, 
this is probably dependent on the positions of the substitutions. From the metabolism studies on the 
supporting substance 3-acetylpyridine, the major metbolic pathway for 4-acetylpyridine [FL-no: 
14.089] is expected to be via reduction of the keto group followed by conjugation by glucoronic acid 
and excretion via the urine. To a minor extend, N-oxidation or N-methylation may take place. 2-
Hydroxypyridine [FL-no: 14.118] is expected to be excreted as such or as conjugate. 
Subgroup 5: Nicotinic acid is a vitamin metabolite of the candidate substances ethyl nicotinate and 
isopropyl nicotinate. Nicotinic acid reacts with 5-phosphoribosyl-1-pyrophosphate to form the 
nicotinic acid mononucleotide, which then condenses with ATP to form the nicotinic acid analogue of 
NAD, which is subsequently converted to NAD by a reaction with glutamine and ATP.  
Two of the candidate substances [FL-no: 14.110 and 14.120] in this group are expected to be 
metabolised to innocuous products. For the remaining 22 candidate substances of this flavouring group 
[FL-no: 14.085, 14.088, 14.089, 14.092, 14.093, 14.103, 14.104, 14.105, 14.106, 14.115, 14.116, 
14.117, 14.118, 14.124, 14.125, 14.131, 14.134, 14.135, 14.136, 14.140, 14.143 and 14.150] the Panel 
would expect metabolites as N-oxides, epoxides or iminium intermediates. For the 22 candidate 
substances it cannot be anticipated that they will be metabolised to innocuous products or excluded 
that they might be converted to toxic metabolites or intermediates. 
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ABBREVIATIONS 
ATP  Adenosine Triphosphate 
BSO  Buthionine-sulphoximine 
bw  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
GSH  Glutathione  
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAC  N-acetylcystein 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
OECD  Organisation for Economic Co-operation and Developmen 
SCF  Scientific Committee on Food 
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TAMDI Theoretical Added Maximum Daily Intake 
WHO  World Health Organisation 
